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ABSTRACT
Since the emergence of modern biotechnology, the production of recombinant pharmaceutical
proteins has been an expanding field with high demand from industry. Pharmaceutical proteins
have constituted the majority of top-selling drugs in the pharma industry during recent years.
Many of these proteins require post-translational modifications and are therefore produced using
mammalian cells such as Chinese Hamster Ovary cells. Despite frequent improvements in
developing efficient cell factories for producing recombinant proteins, the natural complexity of
the protein secretion process still poses serious challenges for the production of some proteins at
the desired quantity and accepted quality. These challenges have been intensified by the growing
demands of the pharma industry to produce novel products with greater structural complexity and
increasing expectations from regulatory authorities in the form of new quality control criteria to
guarantee product safety.
This thesis focuses on different aspects of the protein secretion process, including its engineering
for cell factory development and analysis in diseases associated with its deregulation. A major
part of this thesis involved the use of HEK293 cells as a human model cell-line for investigating
the protein secretion process by generating different types of omics data and developing a
computational model of the human protein secretion pathway. I compared the transcriptomic
profile of cell lines producing erythropoietin (EPO; as a model secretory protein) at different
rates to identify critical genes that potentially contributed to higher rates of protein secretion.
Moreover, by performing a transcriptomic comparison of cells producing green fluorescent
protein (GFP; as a model non-secretory protein) with EPO producers, I captured differences
specifically related to secretory protein production. I sought to investigate further the factors
contributing to increased recombinant protein production by analyzing additional omic layers
such as proteomics and metabolomics in cells that exhibited different rates of EPO production.
Moreover, I developed a toolbox (HumanSec) to extend the reference human genome-scale
metabolic model (Human1) to encompass protein-specific reactions for each secretory protein
detected in our proteomics dataset. I could predict the top host cell proteins (HCPs) that compete
with EPO for metabolic and energetic resources by generating cell-line specific protein secretion
models and constraining the models using metabolomics data. Finally, based on the detected
patterns of changes in our multi-omics investigations combined with a protein secretion
sensitivity analysis using the metabolic model, I identified a list of genes and pathways that
potentially play a crucial role in recombinant protein production and could serve as promising
candidates for the targeted cell factory design.
In another part of the thesis, I studied the link between the expression profiles of genes involved
in the protein secretory pathway (PSP) and various hallmarks of cancer. By
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implementing a dual approach involving differential expression analysis and eight different
machine learning algorithms, I investigated the expression changes in secretory pathway
components across different cancer types to identify PSP genes whose expression was associated
with tumor characteristics. I demonstrated that a combined machine learning and differential
expression approach have a complementary nature and could highlight key PSP components
relevant to features of tumor pathophysiology that may constitute potential therapeutic targets.
Keywords: protein secretion, integrative omics analysis, genome-scale modeling, protein
secretion modeling, cancer protein secretory pathway, erythropoietin, HEK293
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In the study of living organisms, systems biology considers the interactions between components
of a biological entity and interprets the whole system’s behavior in light of these interactions
(Tavassoly, Goldfarb, and Iyengar 2018). Thus, systems biology as a scientific field could have
different beginnings depending on the context and the scope of system-level thinking. However,
considering specifically the term “Systems Biology” shows its emergence during the mid-sixties
(Rosen 1968). In that time, the development of novel molecular biology methods and the
emergence of high-throughput molecular identification approaches helped in collecting data from
various biological pathways and enabled scientists to more precisely study cellular phenomena
(Schena et al. 1995; Gygi et al. 1999). Soon, many scientists considered the need for holistic
analyzing approaches that could implement all available data to study complex biological
pathways and understand the underlying biological mechanisms.
The protein secretion process is among the most complicated pathways within cells. In human
cells, more than 500 proteins support the core functionality of the secretory pathway for the
production and processing of proteins (Feizi et al. 2017). This complexity highlights the need to
apply a systematic approach in studying protein secretion through a holistic discipline by
considering all network components.
The protein secretion process
Depending on their role and function, proteins can exist in diverse subcellular locations (Yang et
al. 2014). There are different mechanisms that cells use to localize newly synthesized proteins
(Park et al. 2011). The classical pathway involves orientating proteins to their appropriate
destination using a signal peptide sequence on the primary protein, which is then recognized by
transport proteins (Russell and Keiler 2007). Based on the signal sequence, various transport
proteins are specific for different organelles or locations within the cell (Gomez-Navarro and
Miller 2016). Correct sorting of proteins is crucial for cell viability since the failures in this
process may lead to cellular dysfunction and disease (Hung and Link 2011). For example,
Zellweger syndrome, Adrenoleukodystrophy (ALD), Refsum disease, and Parkinson's disease are
associated with a failure to localize one or more specific proteins properly; either within the cells
of a single tissue or in the whole body (Brown and Breton 2000).
Although most proteins are localized in the intracellular space(The UniProt Consortium 2017),
some proteins possess a signal peptide guiding them to pass through the cell membrane and be
exported outside the cell. These proteins are called secretory proteins and can have a wide range
of roles for interacting with their surrounding environments (Uhlén et al. 2019). For example,
hormones and signal peptides facilitate communication with other cells, antimicrobial peptides
defend against invading factors, and digestive enzymes break down environmental resources and
prepare them for uptake. The roles of secretory proteins are thus essential for cell physiology.
Furthermore, understanding the protein secretion pathway is necessary for synthesizing and
translocating desired secretory proteins with great economic/pharmaceutical value.
1
Out of the approximately 20,000 protein-coding genes in the human genome, more than one third
(7,729) are predicted to either have a secretory signal peptide and be secreted out of the cell or
have a transmembrane domain and be inserted into the cell membrane (Uhlén et al. 2015; Thul et
al. 2017). The process of protein secretion begins with transferring newly synthesized secretory
proteins into the endoplasmic reticulum (ER), followed by subsequent modification in the Golgi
apparatus and exporting via secretory vesicles (Alberts 2017). Thus, there are many steps across
different cellular compartments, from translation initiation to releasing secretory proteins outside
the cell (Figure 1).
Figure 1. Metabolic map of the protein secretion process in human cells. The protein secretion process
is a cross-compartmental process within the cell involving many components and tight connections with
core metabolism. This map is available in high resolution at metabolicatlas.org.
The protein secretory pathway in human cells
Although secretory pathways are highly conserved from an evolutionary perspective (Mahlab
and Linial 2014), there are important differences between yeast and mammalian cells (Feizi et al.
2013). Here I summarize the general secretory process in human cells, and in the next section, I
will discuss differences in secretory pathways among bacteria, yeast, and human cells.
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Translocation of proteins to ER
For most secretory proteins, the ER serves as a gateway to enter into the secretory process. As
mentioned in the previous section, the main trigger for targeting a newly synthesized protein to
the secretory pathway is the interaction between the signal peptide and its recognition particle
(SRP). The signal peptide guides secretory proteins and targets them into the ER, where folding
and post-translational modifications (PTMs) occur (Aviram and Schuldiner 2017). To transport a






Because the signal peptide in newly synthesized proteins is on the amino terminus of the protein,
co-translational translocation starts as soon as the signal peptide emerges from the ribosome in
the early translation steps (Lars Ellgaard et al. 2016). After SRP recognizes the signal peptide,
the process of translation pauses, and the ribosome-protein complex is transferred to an SRP
receptor on the ER. The process of signal peptide recognition by SRP is GTP-dependent. Binding
SRP to SRP receptors on ER membranes causes ribosome-protein complexes to sit on translocon
protein in the ER membrane (Skach 2007). Translocon serves as a conducting channel and is
composed of the Sec61 translocation complex, one of the highly conserved proteins present in all
domains of life (Gogala et al. 2014). This protein complex transports proteins into the ER in
eukaryotes and out of the cell in prokaryotes (Gogala et al. 2014). As soon as the signal peptide
of the nascent protein has been translocated into the translocon, signal peptidase in the ER
membrane will cleave the signal peptide (S. J. Walker and Lively 2013). After signal peptide
cleavage, the remaining protein continues entering into the ER lumen and the folding process
begins to take place simultaneously. Chaperon proteins first cover the newly synthesized protein
(Beissinger and Buchner 1998). Chaperons mainly inhibit the aggregation of newly synthesized
proteins and prevent them from forming a nonfunctional structure (Beissinger and Buchner
1998). These proteins also assist with covalent folding and correct assembly of nascent protein,
in addition to many other supportive functions (Saibil 2013).
Post-translational translocation
For a few secretory proteins and most of the proteins targeting other organelles like the nucleus
and mitochondria, translocation occurs after translation. In post-translational translocation, the
Sec61 protein in the ER membrane recognizes the signal peptide of the newly translated protein
(Johnson, Powis, and High 2013). After signal peptide recognition by Sec61 and passing the
protein through its lumen, the signal peptidase protein cleaves the signal peptide. Sec61 is located
near to Sec62/Sec63 complex in the ER membrane, which acts as an activator for the ATPase
activity of BiP proteins. BiP proteins bind non-specifically to proteins entering the ER lumen and
prevent them from sliding back into the cytosol (Johnson, Powis, and High 2013).
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Tail-anchored translocation
The last pathway for the translocation of proteins into the ER is tail-anchored translocation. This
route is also SRP-dependent, but in this case, SRP recognizes the signal peptide located very
close to the carboxy-terminal of the protein. Because the signal peptide is close to the
carboxy-terminal, the ribosome must first release the protein before targeting the protein to the
ER (Hegde and Keenan 2011).
Protein folding and post-translational modifications in the ER
Many proteins in the ER begin post-translational modification of nascent protein as soon as the
protein enters into the ER (Wilk-Blaszczak n.d.). However, protein folding also occurs after
entering the ER and after signal cleavage (Stevens and Argon 1999). Therefore, it is crucial to
recognize that protein folding and post-translational modification do not occur in strict sequential
order (Monte, del Monte, and Agnetti 2014). Protein modification can influence protein folding,
which can, in turn, affect available sites for protein modification (Monte, del Monte, and Agnetti
2014). This phenomenon is very well explained and visualized in the review by (Braakman and
Hebert 2013). The process and interaction between folding and modifying a protein will continue
until it fully translocates into the ER (Mahlab and Linial 2014). Afterward, other
post-translational modifications will continue to prepare for transportation into the Golgi
apparatus (Alberts et al. 2002a), which often occurs through budding transport vesicles (Alberts
et al. 2002a). Alternatively, there are some mechanisms in the ER for retro-translocation from ER
to cytosol in case a protein fails to attain its desired conformation through the folding steps (Tsai,
Ye, and Rapoport 2002). These proteins receive a ubiquitin tag and will be directed to
proteasomes for degradation (Hochstrasser 1996).
Protein folding is highly dependent on spatial conditions. As soon as a protein has enough space,
interactions between different protein domains will begin (McLeish 2005). On the other hand,
having enough space in an environment with a high number of similar proteins or proteins with
similar domains will dramatically increase the risk of misfolding and aggregation (McLeish
2005). Cells use heat shock proteins (HSPs) as chaperons and BiP to reduce this risk (Pobre,
Poet, and Hendershot 2019). The other evolutionary solution to decrease the risk of protein
misfolding is limiting the translation rate relative to folding and post-translational modification
(Alexander et al. 2019). The translation rate for eukaryotic proteins is 4 to 5 residues per second.
At the same time, in prokaryotic cells, it is much higher and is attributed as one of the reasons
that eukaryotic proteins do not fold properly in prokaryotic hosts (Ross and Orlowski 1982).
Many secretory proteins carry N-linked glycans. The majority of modifications occur in the ER
lumen by the specific machinery designed for this purpose (Aebi 2013). PTMs are usually added
co-translationally following synthesis after 15 amino acids have entered into the ER lumen
(Braakman and Hebert 2013). The glycosylation sites on the protein sequence are usually on an
Asn residue in an Asn-X-Ser/Thr sequence (Lowenthal et al. 2016). Oligosaccharyltransferase is
the enzyme responsible for transferring a glycan structure from ER membrane to an Asn residue
in the nascent protein. Glycan structures are synthesized through the dolichol synthesis pathway
in the ER membrane (Burda and Aebi 1999). The N-linked glycosylation is necessary for the
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correct folding of proteins and increasing the stability of the protein (Hanson et al. 2009). From a
conformational perspective, most glycans are on the protein’s surface but can also be added to
other locations on the protein structure (Lowenthal et al. 2016). Sites of glycosylation are highly
protein-dependent (An, Froehlich, and Lebrilla 2009). Besides glycosylation sites, the total
number of glycosylations on a protein surface could also be an essential feature for keeping a
protein functional and stable (An, Froehlich, and Lebrilla 2009).
Quality control mechanisms in the ER
To exit from the ER, proteins should be properly folded and assembled, particularly if they are
members of a multi-subunit complex (Araki and Nagata 2011). Other proteins without these
qualifications still need to remain in the ER to be appropriately processed and folded (Liu et al.
2018). Persistently, misfolded proteins will be retrolocated to the cytosol for proteasomal
degradation (Zhai et al. 2020). The quality control step is the main step to ensure that released
proteins are correctly folded and functional. Unfortunately, most proteins that do not pass the
quality criteria fail at this step (Alberts et al. 2002a). Because this step is essential for ensuring
correctly folded and functional proteins, any failures in the quality check process can lead to
different types of diseases (Yoshida 2007).
Targeting matured proteins to the Golgi by COPII-vesicles
After ER, proteins are transferred to the Golgi apparatus for further modifications such as
O-linked-glycosylation and followed by final protein sorting (Alberts 2017). Vesicles responsible
for this transfer from ER to Golgi are COPII vesicles (Jensen and Schekman 2011). COPII
vesicles bud from specialized sites in the ER membrane and leave the ER to reach cis Golgi
(closer site of Golgi to ER) (Verissimo and Pepperkok 2013). During this process, many quality
control steps were assumed to guarantee that only correctly folded proteins leave the ER through
this pathway (L. Ellgaard and Helenius 2001). However, new findings highlight that all the
proteins, even ER-resident proteins, can leak out from ER to cis Golgi (Alberts et al. 2002a).
Secretory proteins have a higher chance of transferring from ER to Golgi due to the presence of
signal peptide for secretion (“Hematology” n.d.). After COPII vesicles leave the ER and reach
the Golgi, they fuse to the cis Golgi to deliver their contents (Jensen and Schekman 2011). Soon
after COPII vesicles fuse with the Golgi, COPI vesicles start budding from cis Golgi to return to
the ER (Hsu, Lee, and Yang 2009). It should be noted that COPI vesicles transfer misfolded
proteins back to the ER that has been brought to the Golgi by COPII vesicles (Hsu, Lee, and
Yang 2009). The two vesicle types thus constitute a highly dynamic but controlled process
orchestrated by signal transduction.
Post-translational modifications in the Golgi
The Golgi apparatus consists of compact stacks located close to the nucleus-far site of the ER
(Glick 2000). It has been shown that the structural conformation of the nucleus, ER, Golgi, and
vesicles that move between the ER and Golgi is organized by tubular connections that act as an
infrastructure to maintain this conformation (Presley et al. 1997). Oligosaccharide chains are
processed in the Golgi (Faye et al. 1986). The initial modifications for many N-linked
oligosaccharides first happen in the ER and continue in Golgi (Helenius and Aebi 2001). Besides
oligosaccharides, the other necessary modification in the Golgi apparatus is O-linked
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glycosylation performed by a series of reactions catalyzed by glycosyltransferase enzymes
(Stanley 2011). The complexity of pathways related to post-translational modifications,
specifically different types of glycosylation, arises from their variable nature (Goto 2007).
Whereas other macromolecules like proteins and nucleic acids are synthesized based on a
template, large and complex glycosylation structures with up to 20 sugar units are produced
based on the condition of the cell at the moment the protein passes through the ER and Golgi
(Goto 2007). Currently, a big challenge in the pharmaceutical industry is overcoming the
variability of these glycosylations between product batches. This complex nature of glycosylation
structure formation is also a major challenge in modeling protein secretion processes (Wong
2005).
Transport from the Golgi to the final destination
Exocytosis is the process by which vesicles are delivered from the trans-Golgi to the cell
membrane and secrete proteins into the extracellular environment (Söllner 2003). Depending on
their signal, proteins will be sorted to their final destination after proper packaging in trans Golgi.
Released vesicles from trans Golgi will direct to different cellular compartments or will be
secreted to extracellular space (Guo, Sirkis, and Schekman 2014). After packaging secretory
vesicles, motor proteins use their ATPase activity to push secretory vesicles along microtubules
to reach the planned destination (Hunt and Stephens 2011). Transporting the proteins from trans
Golgi to the plasma membrane is not the only function of secretory vesicles; recent studies have
shown that, for some secretory proteins, a part of protein maturation occurs in the trans-Golgi
and continues within secretory vesicles (Losev et al. 2006). Versus exocytosis, cells regulate the
speed of endocytosis to allocate the required time for proper folding of the content of secretory
vesicles (Alberts et al. 2002b).
Differences in the protein secretion process between yeast and mammalian
cells
Yeast and mammalian cells have a similar structure and steps for the protein secretion process
(Sakaguchi 1997). However, although the main procedures including co-translational
translocation, folding, and N-glycosylation in ER, O-glycosylation in Golgi, ER-associated
degradation, and final protein sorting are very similar between yeast and mammalian cells, there
are still some differences that need to be considered. Here, I summarize the main differences that
are known below:
1. Detection of proteins for ER-associated degradation is based on the pattern of protein
post-translational modifications, which differs between yeast and mammalian cells
(Eldeeb et al. 2019; Dunn 2003).
2. During translocation of proteins to the ER, the main chaperones acting in mammalian
cells are BiP proteins, whereas the counterpart in the yeast cells is Kar2 (Kawaguchi and
Ng 2011).
3. The quality control system in mammalian ER tags misfolded proteins with polysaccharide
tags, while this mechanism in yeast cells is different (Xu and Ng 2015).
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4. Components of COPII vesicles in mammalian cells contain four isoforms of Sec24, but in
yeast cells, there are Sfb2/Sfb33 as homologs of Sec24 in mammalian cells.
Pharmaceutical proteins are among the top-selling drugs
In addition to the importance of the protein secretion pathway from a molecular biology
perspective, broad applications of this pathway in industry and medicine further motivate its
study. For example, in 2020, protein-based drugs constituted almost 25 percent of all new drugs
approved by the FDA (the United States food and drug administration)* (Mullard 2021).
Moreover, most drugs with the highest annual revenue are protein-based (8 out of 10 in 2018,
Figure 2A) (Mullard 2021).
Protein drugs are mainly categorized as monoclonal antibodies, hormones, enzymes, blood
factors, vaccines, antibiotics, and cytokines (Bruno, Miller, and Lim 2013). Peptides and proteins
can target a broader range of molecules, making them powerful drug candidates for targeting
different components in a biological network (Lau and Dunn 2018). Moreover, it is possible to
consider more than one interaction between the protein drug and its target in the drug design
process. More specific interactions increase the selectivity of the drug and prevent potential side
effects by decreasing the off-target interactions with other unwanted molecules (Bruno, Miller,
and Lim 2013).
Meanwhile, therapeutic proteins have a more complex structure and higher molecular weight
than small molecule drugs (< 1 kDa for small molecules compared to 1 to > 10 kDa for larger
proteins). The larger size can cause higher instability of these proteins than small molecule drugs
(Bruno, Miller, and Lim 2013). Furthermore, more increased instability directly causes higher
immunogenicity and a shorter half-life (Pisal, Kosloski, and Balu-Iyer 2010). Various strategies
are under development to overcome these issues, such as adding chemical modifications to
synthesized proteins and applying new formulation approaches. However, the production of
pharmaceutical proteins in itself requires complex manufacturing setups, and adding more steps
will further complicate the manufacturing process (Morrow and Felcone 2004).
-------------------------------------------------
*Comparing the list of new FDA-approved drugs from 2015 to 2020 with the same list from 2019 and 2020 indicates the
observed increase in the number of protein-based drugs has not been because of granting emergency approvals to COVID19
(coronavirus disease 2019) proteins-based drugs.
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The majority of the biologics currently on the market are produced through a cell culture
fermentation process followed by downstream purification steps. The manufacturing process has
a significant effect on the final quality of the product. Different parameters could be optimized to
achieve higher quality and quantity in the protein production process, such as optimizing the
bioreactor system, culturing media, purification, and removing impurities (Y. Ma, Lee, and Park
2020; Giuliani et al. 2011; Raynal et al. 2014). However, one component of this process
significantly impacts the quality and quantity of the final product is the host cell line.
Figure 2. Pharmaceutical proteins are among the top-selling drugs. (A) Eight of the top 10 selling
drugs in 2018 are protein-based. (B) Host cell lines for the production of pharmaceutical proteins.
Eukaryotes produce more than 60% of pharmaceutical proteins, and currently, CHO cells are the preferred
host for the production of more advanced products.
Host cells for producing pharmaceutical proteins
There are many different hosts available for producing recombinant proteins (Dumont et al.
2016). However, the choice of the most appropriate expression system for making one specific
protein depends on its characteristics, the ability of the host cell-line regarding applying the
required modifications, and expected quality control criteria from regulatory bodies (Butler and
Spearman 2014). Eukaryotic hosts are the most popular recombinant protein expression systems
and assist with the production of more than 60% of therapeutic proteins (Figure 2B). Mammalian
cells produce 30% of therapeutic proteins produced in eukaryotic hosts. CHO (Chinese hamster
ovary) cells are the most popular and used explicitly for producing more advanced therapeutics
(Dumont et al. 2016). However, varying needs for producing different proteins have made many
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other host cells available that each meets the requirements for the production of a specific range
of proteins. Here, I review the most popular host cells for producing recombinant protein-based
drugs and briefly summarize their advantages and disadvantages.
Bacteria and yeast
Depending on the target protein, E. coli and yeast can serve as great hosts for producing
biologics. Indeed, the emergence of recombinant pharmaceutical protein production on the
industrial scale started from insulin production in E. coli cells in 1973 (Cohen et al. 1973). After
more than four decades and many developments in genetic engineering tools and bioprocessing
methods, most worldwide insulin is still produced in E. coli. Collectively, E. coli serves as the
host cell for producing approximately 30% (Figure 2B) of worldwide recombinant proteins,
which highlights the suitability of this host for producing many proteins that do not have
complicated folding or post-translational modifications in their structure (Baeshen et al. 2014;
Berlec and Strukelj 2013; Dumont et al. 2016). Low cost and an efficient culturing process
combined with the simplicity of genetic engineering via well-developed toolboxes make this host
a powerful cell factory for producing a wide range of products (Mattanovich et al. 2012;
Martínez et al. 2012).
As a eukaryotic host, yeast cells benefit from many of the same advantages as E. coli and possess
the ability to perform post-translational modifications and folding steps for many products at a
level that meets the quality control criteria (Martínez et al. 2012). PTMs play an essential role in
the interaction of therapeutic proteins with their target, and a lack of proper PTMs, specifically,
glycosylation can affect protein stability (Duan and Walther 2015). In addition, yeast cells benefit
from both the efficient and fast culturing process and mimic human PTMs at an acceptable level
for a group of products (Martínez et al. 2012). In most cases, if producing a protein in yeast cells
satisfies quality control criteria, production of the recombinant protein would be more
cost-effective than the production of the same product in other host cells, including mammalian
cells (Martínez et al. 2012). However, despite a vast and growing number of research studies for
improving yeast cells to perform more similar PTMs to human cells (Vieira Gomes et al. 2018;
Huertas and Michán 2019; Šoštarić and van Noort 2021; Thak et al. 2020; Weis, Hartner, and
Glieder 2006), there are still many proteins that suffer from poor quality when produced in yeast.
CHO cells
The natural ability of mammalian expression systems to perform the required modifications on
proteins with high similarity to those in human cells makes these expression systems the
preferred host for recombinant therapeutic protein production (Figure 2B). Among mammalian
expression systems, CHO cells account for producing approximately 70% of therapeutic proteins,
which indicates the importance and applicability of this cell factory in the current niche of the
therapeutic protein production industry. The advantages of CHO cells over other mammalian
hosts are summarized below:
I. High specific productivity (q) in CHO cells compared to other mammalian cells (Kim,
Kim, and Lee 2012), as well as the high viable cell concentration in the cell culture
process, which leads to a higher biomass of the cells (O’Callaghan and James 2008).
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II. CHO cells have shown good genome stability (Worton, Ho, and Duff 1977; Malm et al.
2020).
III. Long years of using CHO cells have established this group of cell lines as a well-known
and safe cell factory for regulatory institutions and has resulted in faster approval of new
proteins produced in CHO cells (Kim, Kim, and Lee 2012).
IV. CHO cells can produce proteins with high similarity to natural human proteins (Kim,
Kim, and Lee 2012). However, CHO cells have also shown a failure to produce some
specific proteins: called difficult to express proteins (Tegel et al. 2020).
V. CHO cells have the advantage of easy adaptation to growth in serum-free culture media,
which is preferred from a regulatory perspective. The ability to grow in suspension
conditions in large-scale bioreactors is one of the fundamental requirements that a host
cell factory needs to be used on an industrial scale (Xing et al. 2009).
Besides the different advantages of CHO cells listed above, the failure to properly fold some
recombinant proteins (Le Fourn et al. 2014) and the observed deviation from natural human
PTMs in some cases (Jenkins 2007) has motivated recent studies for (I) improving CHO cells to
perform the required folding and post-translational modifications on desired proteins (Jenkins
2007; Jenkins, Murphy, and Tyther 2008; S. Fischer, Handrick, and Otte 2015; Le Fourn et al.
2014) or (II) developing alternative cell factories that could naturally perform folding and
post-translational modifications with high similarity to those occurring in human cells, which are
also able to produce proteins with high specific productivity (Dumont et al. 2016).
HEK293 cells
In a recent large screening study (Tegel et al. 2020), it was shown that out of the 2,189 predicted
human secretory proteins, CHO cells could produce 1,276 proteins (58%) without additional
protein-specific optimization. The remaining proteins failed due to different reasons such as
aggregation, degradation, and folding problems. Specifically, the failure in the production of 126
of these proteins was identified as protein degradation. By switching their production in HEK293
cells, it was possible to produce 86 of the 126 proteins (68%), suggesting that HEK293 cells
could be considered a competent alternative for producing difficult to express proteins in CHO
cells.
HEK293 cells are the most popular human-derived cell factory used to produce proteins on an
industrial scale. Besides the ability of HEK293 cells to produce a good number of difficult to
express proteins in CHO cells, there are some additional advantages HEK293 cells have over
other mammalian hosts:
I. High growth rate and cell density are comparable with CHO cells (Schwarz et al. 2020;
Liste-Calleja, Lecina, and Cairó 2013).
10
II. The flexibility of HEK293 cell metabolism supports growth in different conditions
(Román et al. 2016; Saghaleyni et al. 2020).
III. HEK293 cells can make an identical pattern of PTMs with natural PTMs in human cells
(Goh and Ng 2018). However, this feature depends on the recombinant proteins of
interest (Böhm et al. 2015).
Despite the advantages of HEK293 cells, the lower specific productivity of this cell-line
compared to CHO cells has lowered the popularity of these cells among protein manufacturing
companies. Also, its genome instability has raised concerns among regulatory institutions
because HEK293 cells are not as well studied or established as CHO cells in the context of
recombinant protein production (Y.-C. Lin et al. 2014).
Finally, to leverage the natural ability of HEK293 cells to perform human-consistent PTMs and
proper folding of recombinant proteins, and to consider this cell-line as an adequate alternative to
CHO cells, two main challenges need to be addressed: (I) improving our knowledge about the
differences in the genome of different HEK293 cell types to better understanding how their
genome instability could affect the cell phenotype and gene expression profile (II) further
development of HEK293 cells from a recombinant protein production perspective to improve the
specific productivity of the recombinant proteins.
Deficiency in the protein folding process leads to proteopathy diseases
Another benefit of studying the protein secretion process is to understand better its involvement
in diseases where a deficiency in the production of one or a group of proteins causes a systemic
failure in the functionality of a group of cells in a tissue (Figure 3) (Dugger and Dickson 2017;
Jucker and Walker 2013). A failure to produce some proteins could cause a structural or
functional abnormality within the cell and lead to a wide range of disorders (L. C. Walker and
LeVine 2012). Diseases that are caused by such abnormalities are called proteopathies.
Depending on the misfolding and tissue of origin, proteopathic diseases could lead to different
cell responses and different symptoms at the organismal level (Levenson, Sturm, and Haase
2014). For example, the abnormal folding and deposition of proteins in the brain is the potential
cause of a variety of neurodegenerative diseases, including dementia spectrum disorders such as
Alzheimer’s disease (AD), Huntington's disease (HD), and Parkinson's disease (PD) (Price,
Borchelt, and Sisodia 1993). Proteopathic disorders are not limited to neurodegenerative
diseases; for example, abnormal extracellular deposition of polymeric insulin fibrils causes the
emergence of a group of symptoms classified as insulin-derived amyloidosis (Gupta, Singla, and
Singla 2015). There are many other examples of proteopathic diseases that repeat the same
pattern of misplacing incorrectly folded proteins inside or outside of the cell and interfering with
the natural processes of the cell (Luheshi, Crowther, and Dobson 2008).
The exact reason for misfolding of proteins and the generation of aggregates is uncertain in many
proteopathic disorders and has remained at the level of speculation and discussing different
hypotheses that may better fit the available evidence (Long and Holtzman 2019). However, it is
generally understood that the level of misfolded intracellular proteins will progressively increase
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with worsening symptoms in patients suffering from such diseases (Bogdanovic et al. 2020). So,
based on the best of our current knowledge, the leading cause of the emergence of proteopathic
diseases probably is the lack of correctly folded proteins (L. C. Walker and LeVine 2012). Hence,
understanding the reasons for misfolding of problematic proteins in such diseases could probably
suggest targets for therapeutic purposes (Figure 3A). However, protein misfolding could be a
byproduct of some other failure in the protein production network, such as a lack of resources to
fold or perform quality control. Therefore, understanding why some proteins misfold requires a
systematic approach that considers the whole protein secretion pathway, of which protein folding
is only one part (Figure 3B).
Figure 3. Deficiency in the protein folding process serves as the main reason for proteopathy
diseases. (A) Aggregated misfolded proteins could cause a defect in cell metabolism and raise the risk of
proteopathy disorders (B) Protein misfolding could happen because of a wide range of reasons, from
metabolic deficiencies to failure in required energy for folding and protein folding machinery.
Current approaches in systems biology of protein secretion
Studying large systems requires information or logical predictions about individual components
as well as the interactions between components. Analyzing the interactions between components
within a system leads to a new understanding of whole-network properties that may not be
possible to infer by studying each component in isolation; in the context of systems biology,
these are called emergent properties of biological networks (Bhalla and Iyengar 1999; B. Palsson
2006). In this way, systems biology approaches aim to consider the organism (cell) as a whole
system rather than an isolated analysis of individual network components (Tavassoly, Goldfarb,
and Iyengar 2018). However, the scope of a system can vary in different contexts, from a small
regulatory network with a few components to global omics analyses that consist of thousands of
proteins and metabolites or even studying multi-cellular microbial communities (Voit 2013).
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In a recent study, Feizi et al. (Feizi et al. 2017) showed that genes encoding the protein secretion
machinery in human cells are expressed in a tissue-specific pattern to meet protein secretion
demands for each specific tissue. Other studies highlight how protein secretion rate and PTM
pattern are affected by the cell culturing condition as well as the status of different pathways
within the cell, such as the composition of culture media, redox homeostasis, apoptotic pathways,
and energy metabolism (Schwarz et al. 2019; Meuris et al. 2014; Del Val, Polizzi, and
Kontoravdi 2016; Liang et al. 2020; Behrouz et al. 2020; Rahimpour et al. 2013). These studies
imply that the protein secretion process, as a large pathway spanning multiple cellular
compartments, has tight connections with the other signaling and metabolic pathways within the
cell (Lodish et al. 2000). Hence, studying such complex processes via reductionist approaches,
which only consider individual components of the network in an isolated setup, is insufficient to
reach a more comprehensive understanding of the protein secretion process. Instead, holistic
approaches that consider all components and their corresponding interactions within and beyond
the pathway may pave the way to discover other mechanisms that govern the protein secretion
process. However, to consider all components of the network in the analysis, we first need
collective characterization and quantification of components within the network, and next
interpret the final state of the network through analysis of collected information for each
component and the interactions between components; what I call omics analysis (Micheel et al.
2012).
In recent years, three landmark achievements in the field of molecular and computational biology
greatly impacted the research and assisted in developing our knowledge about the protein
secretion process: (I) Availability and rapid cost decrease of global omics approaches for high
throughput measurements of molecular components such as genes, proteins and metabolites
(Reel et al. 2021; Lancaster et al. 2020; Sun and Hu 2016; Akiyama 2021) (II) Improvements in
the algorithms for analyzing big data sets using novel comparative and deep learning approaches
(Uhlén et al. 2019; Obudulu et al. 2018; Schinn et al. 2021; D. Lin et al. 2020; Robinson et al.
2019; L. Zhang et al. 2018; Reel et al. 2021; Martorell-Marugán et al. 2019) and (III) emergence
of the CRISPR genome engineering method in addition to other advancements in genetic
engineering tools (Sergeeva et al. 2019; Cong et al. 2013). These advancements paved the way
for testing more ideas more efficiently, thereby accelerating the design-test-investigate loop (M.
Zampieri et al. 2017; Parola, Neumeier, and Reddy 2018; Kweon and Kim 2018; Cupp-Sutton
and Wu 2020; Toby, Fornelli, and Kelleher 2016).
Omics techniques and computational data analysis approaches
Each omics approach captures a different layer of information in the cell, such as the genome,
transcriptome, proteome, or metabolome. Omics technologies generally fall into two main
categories (Figure 4): (I) sequencing-based approaches like genomics and transcriptomics and
(II) mass spectrometry-based approaches like proteomics and metabolomics.
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Figure 4. Methodological background and integrative analyzing disciplines for biological omics
datasets.
Genomics
Genomics was the first introduced omics approach and provided access to the whole DNA
sequence for many organisms. Asa field of study, DNA sequencing started right after discovering
the helical structure of DNA in 1953 (Ankeny 2003). However, it took a couple more decades to
complete the first whole-genome sequence for Haemophilus influenzae, as an individual
organism, in 1995 (Fleischmann et al. 1995). Despite the availability of genome sequencing
technology, until recent years and the availability of next-generation sequencing technologies,
high-throughput genome sequencing was not yet market-friendly (Hall 2007; Church 2006).
However, further technological development drastically decreased the costs associated with
genome sequencing (Hall 2007; Church 2006). The availability of genome sequencing data for
many organisms challenged extracting knowledge from big data in front of biologists for the first
time. It motivated many studies that today are known as the footstones of computational biology
and systems biology (McKusick 1997). For example, developing algorithms for the assembly of
sequenced DNA contigs followed by functional annotation of assembled sequences; topics that
are still under progress and improvements (Pevsner 2009; Pop 2009; Visser et al. 2002; Flicek et
al. 2013). Depending on the research study, huge levels of information could be inferred from
genomic data. For instance, comparative genomics among different organisms and cells could
highlight differences from higher chromosomal structure differences (karyotype) to single
nucleotide polymorphism among different alleles of a gene (Hardison 2003; Ellegren 2008).
Transcriptomics
Transcriptomics approaches also benefit from sequencing-based technologies. A transcriptome
dataset consists of a set of reads belonging to RNA molecules transcribed from an organism’s
genome in a specific physiological condition. So, unlike the genomics profile, the transcriptomic
profile of an organism is dynamic and changes with time and the physiological status of the
system (Supplitt et al. 2021). In addition, the transcriptome can also capture the effect of
alternative splicing and detect transcripts that belong to the same gene (J. Wang et al. 2015).
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Currently, there are two leading technologies for generating transcriptome libraries: (I)
microarrays, which is a relatively older technique that uses a set of pre-defined sequences for
detecting reads in the samples (Chang 1983), and (II) RNA-seq, which is a newer and more
common approach which benefits from high-throughput sequencing to decipher all transcripts
and match them in downstream processing to a corresponding reference genome or a predefined
set of transcripts (Chu and Corey 2012; Z. Wang, Gerstein, and Snyder 2009; Dobin et al. 2013;
Patro, Mount, and Kingsford 2014; Wu and Watanabe 2005).
Another recent breakthrough technology in the field of molecular biology is to perform
high-throughput sequencing analysis at the level of single cells (Adil et al. 2021; Aldridge and
Teichmann 2020; Andrews et al. 2021). Specifically, transcriptome profiles of individual cells on
a large scale enable investigation of cellular heterogeneity that is not possible when using bulk
samples (Y. Wang and Navin 2015).
Currently, differential gene expression analysis is the most common approach for analyzing
transcriptome data; comparative analysis of samples categorized in two or more groups and
finding genes that exhibit statistically different expression levels between groups (McDermaid et
al. 2019). Different approaches have been introduced for performing differential expression
analysis between samples, each applying different assumptions (McDermaid et al. 2019; Quinn,
Crowley, and Richardson 2018; Li 2019). Briefly, all approaches for the comparative analysis of
transcriptome profiles consider the following parameters to define the proper statistical method:
(I) a small number of replicates due to the laboratory limitations in producing biological samples
(II) wide range of expression for a gene between different samples and also for different genes in
a sample (III) presence of outliers that could be because of high difference in expression for a
gene between samples or because technical noise and (IV) non-normal distribution of raw count
data (Love, Huber, and Anders 2014; McCarthy, Chen, and Smyth 2012). The final result of
differential expression analysis is generally a table of gene expression fold changes and the levels
of statistical significance associated with the fold changes.
Mass spectrometry-based omics approaches: proteomics and metabolomics
Unlike sequencing-based approaches, global untargeted metabolomics and proteomics, which
measure different classes of biomolecules in a sample, are both based on mass spectrometry
(MS) approaches (Blum, Mousavi, and Emili 2018). MS is used to determine the molecular
weight of different ions by measuring the mass-to-charge (m/z) ratios (Parker, Warren, and
Mocanu 2011). The molecules in a sample must, therefore, first be converted to the gas phase.
Then, a mass analyzer component separates ionized species based on their difference in m/z ratio.
Finally, an ion detector detects and generates a signal proportional to the m/z ratio for each
molecule (Parker, Warren, and Mocanu 2011). In omics analysis, the first MS run often continues
with additional MS rounds on each of the detected analytes to further investigate the level of each
analyte in the samples (called tandem MS or MS/MS). For this purpose, before MS
measurements, fragmented peptides must first be labeled for each sample. Then, by running
additional rounds of MS, one can detect the ratio for each ion between two samples in a group of
samples (Di Girolamo et al. 2013). Due to the complexity of biological samples, one suggested
additional preprocessing step is the fractionation of samples and decreasing the number of ions in
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each fraction. For example, using liquid chromatography (LC), each sample can be separated into
more fractions. Then by performing MS/MS on each fraction, a higher number of molecular
species can be detected. LC-MS/MS is currently one of the standard approaches for performing
proteomics and metabolomics analysis on biological samples (Di Girolamo et al. 2013). Finally,
by summing up the measured intensity ratios for all species belonging to a known molecule, the
final intensity ratio table for all detected proteins or metabolites can be calculated.
The final result of LC-MS/MS analysis is a table of ratios for each protein or metabolite. Ratios
indicate the level of detected intensity for each protein or metabolite between a case sample and a
reference sample (Taverna and Gaspari 2021), which usually serves as a pool of all samples in an
experiment as a baseline. The bioinformatic approaches for analyzing the raw results of
proteomics and metabolomics are not as standardized as those for transcriptomics and genomics
analysis. However, comparative analysis for finding molecules with a statistically significant
pattern of change between samples, followed by enrichment analysis for finding enriched
pathways with significantly different proteins or metabolites, can help to reveal the pattern of
alterations in metabolism and physiology between two samples.
Integrative omics analysis
Each type of omics data is like a cross-sectional layer of information from the system under study
(Subramanian et al. 2020; Das et al. 2020) (Figure 4). Although each layer profoundly improves
our knowledge regarding similarities and differences between samples in an experiment, only
specific types of biological information emerge in each single omics analysis. Thus, a further
advantage in multiple omics analysis studies could be acquiring higher levels of biological
insight by applying integrative omics approaches that bridge remarkable findings between
individual omics layers and fill the gap in our knowledge between observed genotype and
phenotype of cells.
The main challenges in integrative omics analysis are as follows: (I) The coverage of detected
molecular species may vary in different mass spectrometry analyses, which causes heterogeneous
data coverage for different samples. The same issue exists in transcriptomics analysis as well,
specifically newer approaches for single-cell analysis (Martorell-Marugán et al. 2019) (II) Each
omics dataset has its specific formalism and needs proper data treatments like normalization and
managing missing values before entering to omics integration pipelines (Mertens 2017; Nusinow
and Gygi 2020; Misra et al. 2018). (III) The variance of measurements is different between omics
datasets (Boccard and Rudaz 2016). For instance, in many transcriptomics studies, the absolute
logarithmic fold change higher than 1 (|Log2FC| > 1) is considered a cut-off for DE genes. In
contrast, in proteomics datasets, the variance of changes is much lower than transcriptome, and
there is no agreed cutoff for fold change in research with proteomics analysis. The different
dynamic ranges between different omics layers is thus an important consideration when
performing an integrative analysis. (IV) In biological studies, the number of measured features
(genes, proteins, metabolites, etc.) is often more than the number of samples. This causes a
high-dimensional space with many correlated features that may complicate or interfere with
many downstream analyses (Subramanian et al. 2020). To overcome this challenge, dimension
16
reduction methods such as PCA (principal component analysis) (Jolliffe and Cadima 2016) and
LDA (linear discriminant analysis) (Tharwat et al. 2017) can be used.
Omics data integration can be performed sequentially or simultaneously (Bersanelli et al. 2016;
Subramanian et al. 2020). In the former, algorithms perform tests on omics layers in sequential
order. Significant alterations in each omics layer in agreement with findings on the previous
layers will be selected to detect modules changing across all omics layers between two sample
groups. On the other hand, simultaneous multi-omics integration approaches secure high
sensitivity in considering all relationships between variables but minimize the use of existing
knowledge about variables in different omics layers (Silverbush et al. 2019).
Another approach to categorize multiple omics integration methods is based on their
mathematical aspects (S. Huang, Chaudhary, and Garmire 2017). From a mathematical
perspective, omics integration methods can be classified into three different groups (Figure 4): (I)
concatenation-based integration methods, (II) model-based integration methods, and (III)
transformation-based integration methods (Reel et al. 2021). In addition, the level of supervision
could vary from supervised to semi-supervised to unsupervised and depends on the specific
approach (“Handbook of Statistics” n.d.; Stein-O’Brien et al. 2018; Wilson et al. 2019; Bersanelli
et al. 2016).
Concatenation-based integration
Concatenation-based integration approaches simply combine matrices from different omics
datasets to generate a joint matrix. Once the joint matrix is generated, it will be used for
downstream supervised or unsupervised analysis (Reel et al. 2021). Because of the high number
of variables in the joint matrix, a feature selection step is usually necessary before any
downstream machine learning analysis (Sorzano, Vargas, and Pascual Montano 2014). The
reduced joint matrix could be used as input for different supervised (e.g., decision tree, artificial
neural network, random forest, etc.) (Quinlan 1993; Domingos and Pazzani 1997; Breiman 2001)
or unsupervised approaches (e.g., non-negative matrix factorization, iCluster, iCluster+,
MoCluster, MOFA, etc.) (S. Zhang et al. 2012; Shen, Olshen, and Ladanyi 2009; Mo et al. 2013;
C. Meng et al. 2016; Argelaguet et al. 2018). Matrix factorization approaches attempt to reduce
dimensionality by inferring a different (smaller) set of variables from the data (Pierre-Jean et al.
2020). The most well-known approach of this type is principal component analysis (PCA).
Canonical correlation analysis (CCA) is another approach that investigates the relationship
between variables in two or more datasets (D. S. Wilks 2011). This approach has been widely
used in omics integration analysis (Rodosthenous, Shahrezaei, and Evangelou 2020). In general,
concatenation-based approaches need proper preprocessing regarding normalization before
concatenation. A disadvantage of these approaches is that they do not consider the potential
differences in distributions among different types of omics datasets. Also, handling a large matrix
of variables from different omics datasets can become computationally expensive.
Model-based integration
In model-based integration approaches, first, multiple intermediate models simulate each of the
omics datasets, and then a final model integrates the intermediate models (Reel et al. 2021).
Since each dataset is first modeled individually, this approach effectively addresses the challenge
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of combining omics datasets because of their methodological differences, such as the variance of
reported values for measured variables and differences in absolute or relative measurements.
Then ML methods can be used to train a general joint model that selects the most important
variables from each model (Drăghici and Potter 2003). Similar to concatenation-based
integration, here, the level of supervision may vary between the different methods. An advantage
of model-based integration approaches is their flexibility in analyzing omics data from different
sets of samples. However, these could be a disadvantage because if omics data are highly
heterogeneous, medium to weak signals could easily be lost (López de Maturana et al. 2019;
Kamisoglu et al. 2017).
Transformation-based integration
In transformation-based integration approaches, each omics dataset is first transformed to a graph
or kernel matrix. Then a joint matrix will be constructed from these matrices (Reel et al. 2021) to
train a machine learning model. These approaches can organize multiple datasets that measure
different variables for a fixed group of samples (Yan, Zhao, and Pang 2017). Also, the
computational cost for these approaches is lower compared to the other two groups.
Modeling approaches
Individual and integrative omics analyses can provide a great deal of molecular information
about a biological system. However, each omics sample only captures the characteristics of a
biological system at a single time point. Therefore, it is beneficial to use predictive tools to
contextualize data obtained from high-throughput experiments and accelerate the
design-test-investigate loop (Nielsen 2017a).
Different approaches exist for modeling the reactions and interactions in a cell and can generally
be categorized as topological, stoichiometric, and kinetic models (Steuer 2007). Topological
models consider the directions and interactions between components in a network. So these
models are mainly limited to predicting global qualitative properties of the network, such as
modules and hub nodes (Najafi et al. 2014). Unlike topological models, kinetic models predict
cell states with quantitative measurements; however, developing kinetic models requires a lot of
experimental data to assign or estimate the many parameter values, which are most often difficult
to obtain or unavailable (B. Ø. Palsson 2011). On the other hand, metabolic models can provide
quantitative predictions and are flexible for contextualizing experimental data if such data are
available (Nielsen and Hohmann 2017; B. Ø. Palsson 2015). Specifically, recent advances in
integrating molecular data with metabolic models have paved the way for using proteomics and
metabolomics data as additional constraints in genome-scale metabolic models (Domenzain et al.
2021; Pandey, Hadadi, and Hatzimanikatis 2019; Yu Chen, Nielsen, and Kerkhoven 2021; Xia et
al. 2021; Yu Chen and Nielsen 2021). In the present thesis, genome-scale metabolic models were
used to study cell metabolism.
Genome-scale metabolic models
A genome-scale metabolic model (GEM) is a mathematical representation of a set of biochemical
reactions in an organism of interest (Nielsen 2017b). Reactions are single units of the model that
consume and produce metabolites and can be associated with one or more genes.
18
Principles
Information about reactions and metabolites comprising the metabolic network of a cell or tissue
is organized in a M✕ N stoichiometric coefficients (S) matrix (B. Palsson 2006), where M is the
number of metabolites and N represents the number of reactions (Figure 5A-B). The S matrix’s
negative or positive values correspond to consumption or production of metabolites in their
corresponding reactions, respectively. Besides reactions annotated from the genome of organisms
and indexed in metabolic databases such as KEGG (Kanehisa et al. 2021) and METACYC (Caspi
et al. 2008), other reactions exist in the S matrix; these reactions mainly have one of the
following roles within the genome-scale models:
I. Lump reactions: these reactions are used for connecting a group of metabolites. The most
commonly used lump reaction in GEMs is the biomass reaction, which consumes
metabolites that comprise the cell biomass. Stoichiometric coefficients in the biomass
reaction are assigned based on experimental analysis of the dry cell composition or based
on estimations from biomass of organisms phylogenetically close to the organism of
interest (Schulz et al. 2021; Mendoza et al. 2019).
II. Exchange reactions: these reactions enable the exchange of metabolites into and out of
the system (Figure 5A-B).
III. Transport reactions: reactions that transport metabolites from one model compartment to
another (e.g., from the extracellular environment to the cytoplasm) (Figure 5A-B).
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Figure 5. Principles of genome-scale metabolic modeling and flux balance analysis (FBA). (A)
Visualized form of a toy metabolic model including exchange reactions, Rex, transport reactions, R1, R2,
and R3, an objective function reaction, Robjective, and intracellular reactions R4-R8. m is used for indexing
metabolites (note the number of consumed and produced metabolites in each reaction) (B) Stoichiometric
matrix (S) representing the toy model in (A). Metabolites are in rows of the matrix and reactions as
columns. Numbers in the stoichiometric matrix correspond to the number of consumed (negative) or
produced (positive) equivalents of each metabolite in each reaction. (C) Visualized flux cone based on the
fluxes of three reactions (R1, R3, and Robj) in the model. (D) Visualized fluxes of reactions based on the
results of FBA analysis. Arrow width represents the flux rate for each reaction.
Compared to other cellular processes such as translation, cell cycle, and replication, metabolism
is a relatively fast process. Therefore, when simulating reaction fluxes using flux balance
analysis (FBA) (Rajvanshi and Venkatesh 2013), it is assumed that a steady-state condition
applies, meaning that the consumption and production for each metabolite must be equal (except
exchange metabolites and biomass) (Nielsen and Hohmann 2017; B. Ø. Palsson 2015). Using the
steady-state assumption and applying other constraints for the consumption or production of
specific metabolites, estimating the flux distribution for all reactions for that system and
condition is possible. However, to calculate the flux distribution, additional assumptions are
required:
I. The minimum and maximum permitted flux for each reaction in the model are
lower-bound (lb) and upper-bound (ub). Thus, the directionality of reactions can be
defined using lb and ub values, where an irreversible reaction has a lb of zero.
II. Changes in extracellular metabolite concentrations over time can be measured and
converted to flux values, which can then constrain the uptake or production of those
metabolites in the model.
The flux range for all reactions together comprises the feasible flux space that satisfies all the
mass balance and thermodynamic constraints (Nielsen and Hohmann 2017; B. Ø. Palsson 2015)
(Figure 5C). This is also called the solution space or flux cone, and each point in this theoretical
space represents a flux vector (v), which defines the flux of each reaction (“Metabolic Flux
Analysis” n.d.). Depending on the study, the optimal solution could be defined as the point in the
flux cone that minimizes (or maximizes) an objective function. This method is known as flux
balance analysis (FBA). For example, the biomass reaction flux is often defined as the objective
function in FBA, assuming that cells (specifically microbial) tend to maximize growth. However,
any reaction or combination of reactions can be used as an objective function. For instance,
minimizing the consumption of ATP, maximizing secretion of a specific metabolite for metabolic
engineering purposes, or minimizing lactate production (Yiqun Chen et al. 2019; Baart and
Martens 2012; Nilsson and Nielsen 2016; Nilsson et al. 2020; Feizi et al. 2013; Gutierrez et al.
2020) are potential objective functions.
Reconstruction
The process of reconstructing a GEM starts from the genome as a library of genes present in an
organism, which are then associated with the reaction(s) that they are known to catalyze. These
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approaches are called bottom-up reconstructions (Thiele and Palsson 2010). Next, by adding
exchange and transport reactions and introducing a biomass reaction, the reactions in the model
can potentially carry flux. However, if all metabolites in the reactions are not connected, it may
lead to gaps in the model and a need for performing gap-filling steps (Fouladiha et al. 2021). This
further complicates the laborious process of reconstructing functional genome-scale metabolic
network models.
To overcome these challenges and accelerate reconstructing GEMs, semi- or fully automatic
approaches have been under development in recent years, aiming to reconstruct a cell-specific
model from various inputs and automate gap-filling steps (Mendoza et al. 2019). Besides
improving the efficiency of GEM reconstruction by such approaches, the quality of reconstructed
models in terms of accuracy of predictions and also reproducibility of the process (Opdam et al.
2017) also increases by using (semi-)automated approaches. In this thesis, I have used the
RAVEN toolbox and INIT algorithm to generate genome-scale metabolic models starting from
transcriptomics data and the generic human GEM, Human1 (Agren et al. 2012; H. Wang et al.
2018; Agren et al. 2014). The INIT is an algorithm that starts from transcriptomics data instead
of the genome to reconstruct specific models based on expressed genes in a transcriptome profile
(Agren et al. 2012).
Human1
Constraint-based modeling of human metabolism has been an active area of interest over the past
couple of decades, where different GEMs have been developed to model human metabolism
(Duarte et al. 2007; H. Ma et al. 2007; Thiele et al. 2013; Brunk et al. 2018; Mardinoglu et al.
2013). The most recent GEM introduced for human cells is Human1 (Robinson et al. 2020).
Human1 integrates all curated data deposited in the previous human metabolic models, has
included higher quality gene protein reaction (GPR) associations, and presents a web portal
hosting the GEM content that enables the overlay of gene or protein expression data on the
pathway- or compartment-level maps.
Further GEM improvements
Since the first developed genome-scale metabolic model in 1999 (Edwards and Palsson 1999),
generating a GEM for organisms is much more efficient and accessible (Gu et al. 2019).
Improving the approaches and algorithms to generate better GEMs with improved power of
prediction and higher coverage of pathways within the cell has always been an active area of
interest (Mendoza et al. 2019; Opdam et al. 2017; Pfau, Pacheco, and Sauter 2016; G. Zampieri
et al. 2019). Efforts to improve GEMs could be categorized as two main categories that both aim
to contextualize information from high-throughput analyses, such as metabolomics, proteomics,
and phosphoproteomics (Figure 6) (Hadadi et al. 2020; Töpfer, Kleessen, and Nikoloski 2015;
Hastings et al. 2019; Töpfer, Seaver, and Aharoni 2018):
I. Improving model predictions by logically constraining reactions and further reducing the
flux cone solution space (Lloyd et al. 2018; Lewis, Nagarajan, and Palsson 2012; Bordbar
et al. 2014; O ’brien et al. 2013; Lerman et al. 2012; Oftadeh et al. 2021; Sánchez et al.
2017). For example, Sanchez et al. (Sánchez et al. 2017) provided an algorithm called
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GECKO, wherein users can constrain the upper bound of reactions using absolute protein
concentrations (from proteomics analysis) and specific reaction rate constant (kcat) for
each protein. The resulting model is called an enzyme-constrained GEM (ecGEM)
(Figure 6A).
II. Improving the coverage of reactions in the model by generating specific reactions for
subcellular pathways that are not cataloged in the classical GEMs, for instance,
translation, lipid production, and protein secretion pathways (Nookaew et al. 2008; Du et
al. 2019; Oftadeh et al. 2021; Loira et al. 2012; Feizi et al. 2013; Gutierrez et al. 2020).
Each of the mentioned approaches has dramatically benefited from the flexibility of GEMs to add
recently discovered biological knowledge, followed by significant improvements in the power of
predictions by the model. In addition, the protein secretion process has also been added to
classical GEMs in multiple studies (Figure 6B).
Figure 6. Genome-scale metabolic model (GEM) improvements. (A) Improving GEM predictions by
applying constraints on reaction fluxes based on proteomics data further limits the solution space. The
resulting model is called an enzyme constrained GEM (EC-GEM). (B) Improving GEMs coverage by
expanding the model to cover reactions and pathways within the cell that are not present in classical
GEMs; for example, the protein secretion process (sec-GEM).
Protein secretion modeling
Modeling of protein secretion processes mainly fall into two groups: (I) modeling the pathways
and reactions that are in charge of translation, folding, and sorting of proteins (Feizi et al. 2013;
Gutierrez et al. 2020; Thiele et al. 2009) and (II) developing models that predict location and
structure of post-translational modifications (PTMs) for each protein aiming for model-derived
glycoengineering (Stach et al. 2019; Spahn et al. 2016; Štor et al. 2021). In the latter approach,
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the production process of proteins is not the topic of study. Instead, only discovering and
modeling the logic for producing desired patterns of PTMs is of interest.
Feizi et al. (Feizi et al. 2013) developed the first genome-scale protein secretion model
(secGEM). They began with yeast GEM and adding protein secretion pathway reactions to yield
a functional model capable of producing all detected secretory proteins in yeast. However, each
secretory protein has specific characteristics, and all these proteins are not possible with one set
of reactions. To overcome this challenge, they developed a pipeline that generates a particular set
of reactions based on characteristics for each protein and adds these protein-specific reactions to
the reference model. By applying such an approach, they demonstrated that it was possible to
systematically predict the metabolic demand for each secretory protein’s production and
quantitatively estimate each component of the secretory machinery.
More recently, Gutierrez et al. in 2020 (Gutierrez et al. 2020) applied the same approach to
reconstruct secGEMs for Chinese hamster ovary (CHO) cells, human cells (using Recon 2.2
human GEM as reference model), and mice. The model successfully simulated the energetic
costs and machinery demand for the production of each secretory protein. In addition,
simulations suggested alterations in the expression of secretory proteins in various conditions that
were later confirmed by experimental analysis.
In the modeling section of the current thesis,  by taking a similar approach, I developed a toolbox
to expand Human1 to cover protein secretion reactions that are capable of producing all secretory




In paper I, I compared the most popular HEK293 cell lines currently widely used in different
laboratories for protein production. In addition, I compared genome and transcriptome between
different clones and discovered genomic and transcriptomic alterations that could lead to growth
in the suspension condition.
In paper II, I investigated the differences in HEK293 cell metabolism and physiology due to the
production of secretory or non-secretory recombinant proteins. I further explored genes whose
expression correlated with recombinant protein production. I identified a list of genes that
exhibited a significant expression change pattern between different erythropoietin (EPO)
production levels.
In paper III, I continued analyzing secretory recombinant protein production by generating an
omics dataset including transcriptome, proteome, and metabolome for three HEK293F cell lines
that produce EPO at different rates. Using comparative and integrative analyses, I sought to
identify metabolic and signaling patterns that correlate with protein production. Furthermore, I
took a modeling approach and developed a toolbox for constraint-based modeling of the protein
secretion process. I used to find host cell proteins (HCP) that showed the highest competition
with EPO in resource usage. These proteins constituted knock-out candidates with the potential
to improve EPO production.
In paper IV, I investigated changes in the expression patterns of proteins involved in the
secretion process in different cancer types. I performed a comparative analysis and implemented
a machine learning approach to analyze gene expression data from different cancer types. As a
result, I identified critical genes with a clear pattern of alteration between normal and tumor
samples and between samples from different cancer stages.
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Results & discussion
Key genes in cell morphology transformation (Paper I)
To study the protein secretion process in human cells, I chose HEK293 cells as a model cell line
and first aimed to find differences between HEK293 cell lineages. HEK293 cells initially
originated by immortalizing human embryonic kidney cells of an aborted female embryo
transformed by integrating a four kbp adenoviral 5 (Ad5) genome fragment (Graham et al.
1977; Louis, Evelegh, and Graham 1997). HEK293 cells are the most common human cell-line
for the production of recombinant proteins in a wide range of research (Dumont et al. 2016). To
improve recombinant protein production, HEK293 cells have been under development for a long
period, which has led to the establishment of several HEK293 cell lineages (Dumont et al. 2016;
Goh and Ng 2018). In addition, various cell-line engineering strategies and approaches have
resulted in the availability of different adherent and suspension cell lines (Figure 7A) (Malm et
al., n.d.; Graham 1987; Garnier et al. 1994; Côté et al. 1998; Schwarz et al. 2020).
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Figure 7. Overview of the six HEK293 lineages investigated in our study and their relationships. (A)
Genomic and transcriptomic comparisons of HEK293 cells showed a taxonomic divergence between
parental HEK293 and progeny cell lines. Black dots represent adherent cells, and gray dots correspond to
suspension cell lines. (B) PCA of HEK293 cells using the transcriptome shows the separation of progeny
cell-lines and parental cells in the first component of PCA (C) Hierarchical clustering of HEK293 cells by
calculating the Euclidean distance between transcriptomic profiles of different clones (D) Genomic
comparison of HEK293 cells based on the Spearman correlation coefficient of the read counts.
Genomic differences between HEK293 parental and progeny cell lines
Host cell factories in general, and HEK293 cells specifically, exhibit genome instability
(Stepanenko and Dmitrenko 2015; Wurm 2013; Vcelar et al. 2018). Long-term cultivation and
subcloning of cells result in genomic alterations between subclones. To investigate the
differences between HEK293 clones, six industrially relevant HEK293 cell lines were cultured
(Figure 7), followed by sample collection for genomics and transcriptomics analysis. HEK293
cell lines in our study were either adherent (HEK293 parental cell, 293T and 293E) or suspension
(293-F and Freestyle 293-F, 293-H). Hierarchical clustering of transcriptome and genome divided
cell lines based on their morphology into two groups (Figure 7C-D). However, PCA results
showed separation between progeny and parental cell lines in component 1 (Figure 7B),
suggesting genomic divergence between progeny and parental cell lines than among different
progeny lines.
I analyzed genome and transcriptome datasets to investigate differences between HEK293
clones. Genome comparison between clones highlighted a group of genes with the same copy
number gain or loss in the chromosomes of progeny cells compared to parental HEK293 cells
(Figure 8). On chromosome 13 of all progeny cells, a region of > 15 MB was amplified. Seven
protein-coding genes detected in this region exhibited at least a 2-fold increase in the number of
copies in progeny cells. Four out of seven genes (BORA, MZT1, PIBF1, and KLHL1) belonged
to the cytoskeleton gene set. Among other genes with a different copy number between clones,
fumarate hydrolase (FH) showed a copy number loss in some clones (Figure 8 - chromosome 1).
In our analysis, I detected the loss of gene copy numbers for FH and also its neighboring gene
kynurenine 3-monooxygenase (KMO) in 293F, Freestyle 293F, and 293E clones (log2-fold copy
ratio of <-1). The KMO gene has been previously reported for losing gene copies in HEK293
cells and is hypothesized to play a role in the transformation of HEK293 cells (Y.-C. Lin et al.
2014).
Following the observed pattern of common genomic changes between progeny cells and the
parental cell line, I identified SNPs among the genomes of all progeny cell lines compared to the
parental HEK293 cell line. I performed enrichment analysis on common genes with moderate to
high SNP impact. I found significant (adjusted p-value <0.05) enrichment of homophilic cell
adhesion via plasma membrane adhesion molecules (adjusted p-value 0.025) and cell-cell
adhesion via plasma-membrane adhesion molecules (adjusted p-value 0.032). In addition, a
group of significantly differentially expressed genes enriched in the protocadherins protein
family (PCDH12, PCDHB10, PCDHB13, PCDHB15, PCDHB16 PCDHGA2, PCDHGA3, and
PCDHGB2). Although the exact impact of SNPs on these proteins is not well known, enrichment
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of common SNPs within these proteins and between all progeny HEK293 cells may suggest a
specific biological role.
Figure 8. Genomic differences between HEK293 progeny cells and the HEK293 parental cell line.
Red color shows gain, and blue indicates loss over progeny cells compared to parental clones. Gene
names indicate genes that showed the same pattern of gain or loss between all progeny cells compared to
the parental cell line.
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Transcriptomic comparison of HEK293 cells
Pairwise comparison of HEK293 clone transcriptomes showed that the parental clone exhibited
the greatest difference among the cell lines regarding the number of differentially expressed
genes (Figure 9). I detected 329 genes with a constant and significant (Benjamini-Hochberg adj.
p-value < 0.05, absolute log2 fold change > 1) pattern of change, which have different expression
patterns between all progeny cells and the parental cell line. Enrichment analysis revealed that
associate gene ontology (GO) terms with these common DE genes are integral components of the
plasma membrane and cytoskeleton (Benjamini-Hochberg adj. p-value < 0.05). Patterns of
changes in the transcriptome data further confirmed observed differences in the genome analysis.
They highlighted that the main differences between parental HEK293 clones and their progeny
cell lines are related to cytoskeleton matrix organization and cell membrane structure and could
be a selective phenotypic advantage for progeny cells during continuous cell lines cultivation
(Figure 9A).
Due to the importance of the growth morphology of cell lines in industrial bioprocessing, I aimed
to find differences between adherent and suspension cells that lead to the adaptation of adherent
cells to grow in suspension cell culture. Pairwise differential expression analysis of clones
resulted in the detection of 38 genes with a constant and significant (Benjamini-Hochberg adj.
p-value < 0.05, absolute log2 fold change > 1) pattern of change between adherent and
suspension cells (Figure 9B). Furthermore, enrichment analysis of these 38 genes suggested a
potential difference in the cholesterol biosynthetic pathway between adherent and suspension cell
types.
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Figure 9. Pairwise comparison of transcriptomes of HEK293 cells. (A) In a comparison of progeny
and parental HEK293 cells, 329 genes (green) were detected as commonly differentially expressed (DE)
(B.H. adj. p-value < 0.05 and absolute log2 fold change > 1) among all comparisons. Enrichment analysis
highlighted DE genes are associated with integral components of plasma membrane and cytoskeleton. (B)
Thirty-eight DE genes (red in panel A) were detected as commonly differentially expressed in pairwise
comparison of adherent and suspension cells and were enriched in those involved in the cholesterol
pathway.
Focusing on the 38 DE genes between adherent and suspension cells, I aimed to find those genes
that indicate a constant pattern of change between all adherent and suspension cells. For this
purpose, I collected transcriptome data for 63 cell lines from the Human Protein Atlas (Thul et al.
2017) and grouped them based on their morphology, yielding 47 adherent and 16 suspension
cells. Next, I sought to find the pattern of change for 38 DE genes detected in the previous step
(Figure 10). Out of the 38 genes, five genes (LOX, ID1, ZIC1, DHRS3, and RARG) indicated a
consistent and similar expression change pattern (all down-regulated) between adherent and
suspension cells. These genes may play essential roles in the transition from adherent to
suspension morphology. Results presented in this study could be beneficial for further cell-line
engineering purposes and developing cell lines with a morphology switch to shift between
adherent and suspension morphology in desired situations.
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Figure 10. Evaluation of the differential expression pattern for 38 identified differentially expressed genes
in 63 human cell lines. Five genes (LOX, ID1, ZIC1, DHRS3, and RARG) were detected with a consistent
and similar pattern of change. Bars show the logarithmic fold change of genes between two groups of
suspension and adherent cells, and color shows the level of significance. Gray columns represent genes
with an insignificant (p-value > 0.05) change.
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Cell demands for the production of secretory and non-secretory proteins
are different (Paper II)
Higher efficiency of the production process and better quality of the products are ongoing cell
factory engineering research (Tambuyzer et al. 2020). In addition, recent waves in the drug
discovery field have led to the development of new drug proteins with more sophisticated
structures and elevated levels of complexity in the production process (Kintzing, Filsinger
Interrante, and Cochran 2016). However, there are still pending questions regarding the protein
production and secretion process within the cells, such as: what are the differences in metabolic
resource allocation for the production of secretory and non-secretory proteins (Gutierrez et al.
2020), how does energy metabolism need to be rewired to meet the energy requirements for the
production of secretory and non-secretory proteins (M. Huang et al. 2017; Lodish et al. 2000),
and how do cells allocate enzymatic resources to support the demand for production of proteins
(Yu Chen and Nielsen 2019)? Comparing transcriptome profiles of cell lines that produce
secretory and non-secretory proteins at different rates could help address the challenges in
improving the quality and efficiency of the protein production process through designing
improved cell factories. In this study, I established two groups of HEK293F cell lines, producing
either secretory erythropoietin (EPO) or non-secretory green fluorescent protein (GFP) (Figure
11A-B).
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Figure 11. Cloning procedure for generating EPO and GFP producer clones. (A) The schematic
diagram of the cloning procedure results in random integration of recombinant genes (EPO or GFP) and
establishing clones carrying various copy numbers of recombinant genes and different protein production
levels. (B) Transcriptome profiles separate EPO and GFP producer clones in the first component of
principal component analysis (PCA). (C) The growth rate of clones producing EPO and GFP. Range of
specific productivity between EPO producer clones and range of relative GFP production between GFP
producers. (D) EPO mRNA expression versus specific productivity between EPO producer clones.
The growth rates of recombinant protein (r-protein) producer cell lines were lower compared to
the growth rate of their parental cell lines, 22% and 14% in EPO and GFP producers,
respectively. However, the protein production rate showed a more comprehensive range among
clones; Five EPO producer clones exhibited almost a 6-fold difference in their specific
productivity, whereas seven GFP producers showed up to a 4-fold change between the lowest and
highest GFP producer (Figure 11C). Specific productivity of EPO production in EPOF21, the
most productive EPO producer clone, was 13.9 pg/cell-day, which was over 3-fold higher than
the second-highest EPO-producer clone EPO8 (productivity = 4.05 pg/cell.day, Figure 11D).
Interestingly, comparing mRNA levels of the EPO gene between EPOF21 and EPO8 showed a
20% lower mRNA copy number in EPOF21 (Figure 11D).
Energy availability is necessary for recombinant protein production
By comparing the transcriptome profiles of cell lines producing secretory EPO protein with cell
lines producing non-secretory GFP, I found 922 up- and 64 down-regulated genes (B.H. adj
p-value < 0.05, |Log2FC| > 1). In addition, gene set enrichment analysis on the differential
expression analysis results highlighted upregulation (B.H. adj. p-value < 0.05) of protein
secretion-related pathways such as targeting proteins to the endoplasmic reticulum or cell
membrane, as well as some other pathways such as oxidative phosphorylation (Figure 12A).
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Figure 12. Production of secretory EPO needs higher levels of energy. (A) Pathways related to
secretion and oxidative phosphorylation indicate upregulation in EPO producers. (B) Oxidative
phosphorylation is upregulated in EPO producers cells, suggesting an increase in ATP production in these
clones.
Further investigations of the oxidative phosphorylation pathway using Ingenuity Pathway
Analysis (IPA) (Figure 12B) revealed that in EPO producers, all electron transport chain
complexes except complex II were enriched up-regulated genes, which may support higher ATP
production.
Ribosomal components adapt to meet protein production requirements
Another interesting observation in comparing EPO and GFP producers involved the pattern of
expression change among ribosomal proteins. Ribosomal proteins were upregulated in both EPO
and GFP producers (Figure 13A). Further investigations through pairwise comparison of each
EPO and GFP clone with their corresponding controls (Figure 13A) indicated cell lines
upregulate ribosomal proteins in a r-protein-specific pattern. I found common differentially
expressed ribosomal genes (B.H. adj. p-value < 0.05, |Log2FC| > 0.58) in a pairwise comparison
of EPO and GFP producer clones with their corresponding parental cells (Figure 13A). Although
I did not find proteins common in all pairwise comparisons of GFP producers with their parental
control, EPO-producers showed 22 ribosomal genes that were always differentially expressed in
EPO producers compared to their parental clone (Figure 13B). Functionality analysis of these
genes showed that they are mostly related to SRP-dependent co-translational protein targeting the
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ER, indicating a role of these genes in protein secretion. This observation suggests that ribosomal
components are not fixed and confirms previous findings regarding the rearrangement of
ribosomes under different situations to accommodate the translation of different mRNAs (Genuth
and Barna 2018).
Figure 13. Ribosomal genes show a recombinant protein-specific pattern of upregulation in protein
producer clones. (A) Number of common significantly differentially expressed (B.H. adj. p-value < 0.05,
|Log2FC| > 0.58) ribosomal genes between EPO-producers and the parental HEK293F cell. (B) Fold
changes of differentially expressed ribosomal genes between EPO-producers and control.
The availability of multiple cell lines that produce either EPO or GFP but at different rates
enabled us to investigate the correlation between the expression of each gene across clones with
the expression of recombinant proteins in each group. I then investigated the pathways whose
gene expression correlated with the level of recombinant protein production (Figure 14).
Mitochondrial ribosomal genes positively correlate with EPO secretion
By performing a correlation analysis I found 316 genes that showed either positive or negative
correlation (MeanTPM > 10, |Pearson's r| > 0.5, p < 0.05) with EPO production, and 118 genes
correlating with GFP (Figure 14A). I found six genes that showed a significant correlation (|r| >
0.5, p < 0.05) with both EPO and GFP production, mostly involved in post-translational
modifications and regulation of the protein production process (Figure 14B-C). GO term
enrichment analysis (HyperGSA, p < 0.05) of genes correlated with EPO production indicated
protein folding, post-translational protein modification, and post-Golgi mediated transport were
among the pathways enriched with positively correlating genes (Figure 14D). Moreover, the
mitochondrial organization was enriched with both positive and negative EPO correlating genes.
Genes correlated with GFP production mostly showed a negative correlation pattern and were
primarily associated with RNA catabolic processes and RNA export from the nucleus (Figure
14E). The protein translation pathway was enriched (HyperGSA p-value = 0.029) with positive
and negative GFP-correlating genes.
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Many of the genes that negatively correlated with both EPO and GFP production were ribosomal
components. To further investigate, I investigated the correlation of all ribosomal proteins in both
EPO and GFP-producing clones (Figure 14F-G). Interestingly, I found that cytosolic ribosomal
genes (e.g., RPL38 and RPS9) exhibited a negative pattern of expression with increased EPO
production. In contrast, mitochondrial ribosomal genes (such as MRS18A, MRPL49, MRPL40,
and MRS11) showed a positive expression trend with increasing EPO production (Figure 14F).
This is consistent with our previous observation of an upregulation of genes associated with the
electron transport chain in EPO producers. Many upregulated genes in the electron transport
chain have a mitochondrial origin, and mitochondria need ribosomes as translation machinery to
express those genes. Thus, an increased expression of mitochondrial ribosomal genes favors
higher energy production that could support higher EPO production. However, as a trade-off, it is
associated with a downregulation of cytosolic ribosomal components.
I observed a significant shift in the energy metabolism of EPO producers compared to GFP
producers and parental clones (Figure 12). Moreover, I identified a transgene-specific pattern of
ribosomal protein expression (Figure 13), which could be a strategy that cells deploy to adapt to
different situations, such as producing recombinant proteins. I also observed that cells deploy a
strategy to allocate more protein resources to produce more mitochondrial ribosomes while
decreasing the production of cytosolic ribosomes (Figure 14). Although cytosolic ribosomes are
directly needed for r-protein translation, producing more mitochondrial ribosomes may lead to
higher translation of electron transport chain proteins of mitochondrial origin. Consequently,
higher ATP production could indirectly boost EPO production.
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Figure 14. Correlation of gene expression with EPO and GFP production. (A) Negatively and
positively correlating genes with EPO and GFP production. + means positive while – means negative (B)
Common correlating genes with EPO and GFP. (C) Six genes exhibit a correlation between their
expression and EPO or GFP production. (D) GO enrichment analysis of genes that are correlated with
EPO production or (E) GFP production. (F) The trend of correlation for ribosomal genes whose
expression correlates with EPO production or (G) GFP production.
36
Multi-omics of protein secretion by HEK293 cells (Paper III)
In the previous study, I compared each EPO producer clone with EPOF21 at the transcriptome
level to capture unique patterns of changes that could potentially lead to higher EPO production
in EPOF21. Transcriptome enrichment analysis confirmed that significantly changing pathways
between EPOF21 and other lower EPO producers were related to post-translational pathways
such as response to ER stress, response to topologically incorrect proteins and protein catabolic
processes, as well as signaling and metabolic pathways such as mTOR signaling and
carbohydrate metabolic processes (Figure 1G and Figure S6B in paper II). However, functional
diversity of altered pathways suggested that the transcriptome cannot solely explain the
mechanisms behind higher EPO production in EPOF21. Therefore, in a new project (paper III), I
designed an experiment to comprehensively monitor molecular changes in different omics layers
of EPOF21 (a high EPO producer clone), EPOI2 (a lower EPO producer clone), and HEK293F
(the parental clone) (Figure 15A). I collected supernatant samples from each day of culturing for
metabolomics analysis and samples from day four for transcriptomics and proteomics analysis
(Figure 15A). I also measured the EPO production level for both EPO producer clones (Figure
15B). Both EPOF21 and EPOI2 hold two copies of the EPO gene but showed almost a two-fold
difference in EPO production level (7.8 and 4.1 pg/cell.day, respectively, Figure 15B). This
suggests potential differences in metabolic and signaling pathways between the two clones that
confer higher EPO production to EPOF21.
Figure 15. EPO production rate differs between EPO-producer clones. (A) Schematic of design of
experiment (B) EPO production rates vary between EPOF21 (7.8 pg/cell.day) and EPOI2 (4.1
pg/cell.day).
Multi-omics analysis of cells producing EPO at different rates
In a pairwise comparison of transcriptome data between EPOF21 and EPOI2 (Figure 16A),
TNFA signaling via NFKB, cholesterol homeostasis, unfolded protein response, PI3K-AKT
mTOR signaling, mTORC1 signaling, p53 pathway, and UV response pathway showed
significant (B.H. adj. p-value < 0.05) upregulation in the EPOF21 clone compared to EPOI2,
while estrogen early response and apical surface and MYC targets were significantly
downregulated (Figure 16B). Comparison of proteomics data between EPOF21 and EPOI2
(Figure 16C) followed by pathway enrichment analysis revealed upregulation of DNA strand
elongation and replication processes (B.H. adj. p-value = 6.75e-06 and 9.52e-06 respectively) as
well as protein processing in endoplasmic reticulum (adj. p-value = 3.42e-05) and protein export
(adj. p-value = 5.88e-03) in EPOF21. Proteins associated with tRNA aminoacylation and
aminoacyl-tRNA biosynthesis were expressed to a higher extent in EPOI2 (B.H. adj. p-value =
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2.83e-06 and 3.38e-06, respectively). In contrast, proteins associated with the degradation of
valine, leucine, and isoleucine showed lower expression in EPOF21 (adj. p-value = 1.49e-05)
(Figure 16D). In the metabolomics data from day four of culturing (Figure 16E), metabolites
involved in arginine and proline metabolism exhibited significantly different abundances in
EPOF21 compared to both parental and EPOI2 clones (Figure 16F, FDRF21/I2 = 3.94e-05 and
FDRF21/293F = 8.42e-05). Furthermore, the same pattern of changes was observed for glycine and
serine metabolism when comparing EPOF21 with EPOI2 (FDRF21/I2 = 3.94e-05, Figure 16F).
Figure 16. Comparative analysis of individual omics analysis. (A) Differentially expressed genes
between high and low EPO producer clones. (B) Gene set enrichment analysis based on DE genes from
the comparison of EPOF21 with EPOI2. (C) Differential expression analysis of EPOF21 and EPOI2 using
proteomics datasets (D) Enriched KEGG and Reactome pathways based on differentially expressed
proteins between EPOF21 and EPOI2. (E) The number of metabolites with significantly different
abundance in the media on day 4 compared to blank media. (D) Enriched pathways with differentially
abundant metabolites in pairwise comparisons of the three clones.
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Investigating variables in principal component analysis
Clones separated by EPO production ability in principal component analysis (PCA) across all
three blocks of omics data (transcriptome, proteome, and metabolome). In the first component of
PCA analysis, EPOF21 and EPOI2 separated from the parental HEK293F clone, and the second
principal component (PC2) separated EPO producers from each other (Figure 17A). To follow
up, I further investigated variables in omics datasets that contribute most to the separation of
clones (Figure 17B) in PCA. Top contributing variables in PC1 could highlight genes, proteins,
and metabolites important for EPO production. The top contributing variables in PC2 potentially
promote higher production of EPO in the EPOF21 clone.
CTSZ, a lysosomal cysteine proteinase active in terminal degradation of proteins in lysosomes
(Aiba et al. 2018), showed the highest increase in EPOF21 in comparison to EPOI2 (B.H. adj.
p-value < 1.55e-48, Log2FCF21/I2 = 8.82). Other upregulated genes in EPOF21 that showed
substantial contribution in separation between EPOF21 and EPOI2 included ZN726, H2AJ,
MYD88, and CYP7B1. These genes are involved in modulating gene expression through
transcriptional regulation and protein folding (Craig-Mueller et al. 2020; Isermann, Mann, and
Rübe 2020; Huntley et al. 2006).
In the proteomic data, eukaryotic initiation factor 4A-II (EIF4A2) showed the highest difference
between EPO producer clones (Log2FCF21/I2 = 0.56, B.H padj = 0.03) and was the top contributing
protein to PC2. Mitochondrial carbamoyl-phosphate synthase (CPS1) also exhibited significantly
higher expression in EPOF21 (Log2FCF21/I2 = 0.52, B.H padj = 0.01). CPS1 catalyzes the
rate-limiting reaction in the urea cycle, which acts in the production of glutamine, arginine, and
creatine through the biosynthesis of carbamyl phosphate from carbonate and ammonia
(Diez-Fernandez and Häberle 2017). Moreover, the positive effect of CPS1 upregulation on
activating the mTORC1 signaling pathway has been frequently reported (Mossmann et al. 2019).
It could be an indirect effect of higher arginine production that promotes the production of
pyrimidines and creatine (Brosnan and Brosnan 2010; Shuyu Wang et al. 2015; Wyant et al.
2017). Among other top ten proteins that contributed to the second PC, Flotillin-1 (FLOT1) and
general vesicular transport factor p115 (USO1) were upregulated in EPOF21 (FLOT1:
Log2FCF21/I2 = 0.3 and USO1: Log2FCF21/I2 = 0.15, both B.H padj < 0.01). These proteins are
involved in protein vesicle trafficking and protein translocation (Sohda et al. 1998).
Ubiquitin-conjugating enzyme E2J1 (UBE2J1) was also upregulated in EPOF21 (Log2FCF21/I2 =
0.34, B.H padj = 0.01) and is involved in ER-associated degradation of misfolded proteins (Lenk
et al. 2002).
In metabolomics, among the top ten metabolites contributing to the second PC, creatine showed a
substantially higher abundance in EPOF21 (FCF21/I2 = 26.25, B.H padj = 0.008). Moreover,
cytidine, 2'-deoxycytidine, and 5-methylcytidine all exhibited significantly higher levels in
EPOF21 compared to EPOI2 (FCF21/I2 > 1.79 and B.H padj < 0.03), which suggests an activation
of pyrimidine metabolism in EPOF21 relative to EPOI2.
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Figure 17. The principal component analysis separates cell lines based on EPO production. (A) EPO
production ability separates cell lines in principal component 1 (PC1) in all three transcriptome, proteome,
and metabolome datasets, whereas the EPO production level separates EPOF21 and EPOI2 in the second
principal component (PC2). (B) Top ten contributing variables from each omics layer in PC2.
In comparisons of individual omics layers between EPOF21 and EPOI2, the transcriptome
indicated activation of mTORC1 signaling in EPOF21. The metabolome highlighted the higher
production of arginine-derived metabolites such as creatine and polyamines in EPOF21, and the
proteome revealed higher protein processing in the endoplasmic reticulum in EPOF21 (Figure
18A-D). Likewise, further integrative analysis of omics data indicated top contributing variables
in each omics layer are interconnected and suggested a general pattern of change in higher EPO
producer clones. Among the top contributing proteins in PC2, I observed differences in CPS1
expression (Figure 18E), which catalyzes the first reaction in the urea cycle and could promote
the production of arginine-oriented metabolites. Indeed, I observed higher levels of such
metabolites (creatine and polyamines) in EPOF21 among the top contributing metabolites in PC2
(Figure 18A-B). These observations suggest activation of mTORC1 signaling pathways, which
may occur due to the availability of arginine-derived metabolites such as polyamines. mTORC1
improves redox homeostasis within the cell and activates a group of downstream pathways,
including protein production process and cell growth (Figure 18F).
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Figure 18. The general pattern of changes in protein and metabolite production activates the
mTORC1 signaling pathway. (A-D) Arginine-derived metabolites such as creatine, polyamines
(putrescine shown as one of the polyamines), and glutathione (E) CPS1, as the first enzymatic and
rate-limiting reaction in the urea cycle have a higher expression in EPOF21 (F) suggested model of
alterations in EPOF21 that lead to higher EPO production.
Predicting host cell proteins that compete with EPO secretion
Another approach to improve the production level of a recombinant protein (r-protein) in a cell
line is to identify host cell proteins (HCP) that compete with the desired r-protein for metabolic,
energetic, and enzymatic resources (Kol et al. 2020; Gutierrez et al. 2020). Finding HCPs that
compete for most with the production of the r-protein could be performed using a
constraint-based metabolic modeling approach. However, the most updated human reference
genome-scale metabolic model (GEM), Human1 (Robinson et al. 2020), does not cover secretory
pathways and cannot simulate the protein secretion processes. Hence, I drew on the methods
from previous studies (Gutierrez et al. 2020; Feizi et al. 2013; Feizi, Banaei-Esfahani, and
Nielsen 2015; Feizi et al. 2017; Robinson et al. 2019) and developed a systematic approach to
add protein secretion reactions to the Human1 model.
Protein Secretion modeling by HumanSec toolbox
I first developed cell-line-specific GEMs using gene expression data (Mardinoglu et al. 2014).
For generating models, I used the tINIT algorithm implemented in the RAVEN toolbox (H. Wang
et al. 2018) and the Human1 model (Robinson et al. 2020) as the standard reference GEM for
human cells (Figure 19A).
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Protein specific information matrix (PSIM)
To generate protein secretion models, I used the approach developed by Feizi et al. (Feizi et al.
2013) for yeast and later used for CHO cells (Gutierrez et al. 2020). In this approach, I first
collected characteristic information from UniProt for each protein and generated a table of
retrieved information with proteins in rows and protein attributes as columns; this table was
called the protein-specific information matrix (PSIM). The collected information includes
UniProt ID, protein name, ER signal peptide, number of disulfide bonds, number of N-linked
glycosylations, number of O-linked glycosylations, presence of a transmembrane domain, protein
localization information, and protein sequence.
Generating a list of template reactions for the secretory pathway
A list of reactions was generated, covering all potential steps in the process of protein secretion.
To generate such a list of reactions, I reviewed published information regarding components of
the protein secretion pathways and their function in this process (Robinson et al. 2019; Gutierrez
et al. 2020). As different proteins have different characteristics, such as PTMs and different
cellular localizations, the series of reactions comprising the secretory pathway must be tailored to
each specific protein. Therefore, the list of all potential reactions was named the template
reactions list and acted as a library of secretory reactions that could provide the necessary
reactions for the production and secretion of the protein depending on each specific protein.
Reconstruction of the secretory pathway in human cells
I developed the HumanSec algorithm to perform the following steps (Figure 19A): (I) Identify
secretory proteins from proteomics data. The user can decide the criteria for considering a protein
as secretory. In our analysis, I used the presence of an ER signal peptide as the definition of a
secretory protein. (II) Generate a protein-specific list of reactions for each secretory protein using
information contained within the PSIM and the list of template reactions. (III) Add the generated
list of reactions for each secretory protein to a reference GEM. In our case, I used
cell-line-specific GEMs generated by the tINIT algorithm. (IV) Finally, the algorithm performs a
gap-filling step in case of a failure to produce any of the secretory proteins. In general, I added
specific reactions for the biosynthesis and secretion of 559 proteins to GEMs (Figure 19B).
Out of 9,791 proteins, 6,497 were detected in cell pellet samples, and 2,861 proteins were
detected in supernatant samples. The final location predicted for 168 proteins as extracellular,
and 391 proteins were predicted to carry an ER signal peptide in their sequence, suggesting these
proteins are ER and Golgi apparatus clients and need post-translational modification (Figure
19B). By generating protein secretion models that cover reactions for these proteins, 21,760 new
reactions were added to each of the cell-line-specific GEMs.
All codes and functions for generating the PSIM matrix, template reactions list, reconstruction of
the protein secretion model, and overlaying omics data on the protein secretion network map is
archived in a toolbox called HumanSec that can be accessed from its GitHub repository:
https://github.com/SysBioChalmers/HumanSec.
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Constraint-based analysis of reconstructed secretory models
To guarantee the production of all secretory proteins by the protein secretion models generated
for EPOF21 and EPOI2, I used the measured ratios between EPO and each secretory protein in
the proteomics dataset as constraints by defining pseudo reactions connecting the production of
each secretory protein to EPO production. By taking this approach and maximizing EPO
production, the reconstructed protein secretion models produced EPO and all other secretory
proteins in a ratio consistent with the protein abundance ratios measured in proteomics analysis.
I took a similar but more complex approach for constraining the models based on data acquired
from metabolomics datasets. First, I merged the protein secretion models for EPOF21 and EPOI2
(Figure S8 in paper III) and generated one single model representing specific metabolite IDs for
each cell line. Then, I grouped measured extracellular metabolites as either consumed or
produced, based on their change trend in each day of culture. Finally, I defined a stoichiometric
constraint for each extracellular metabolite that forced the two models to consume or secrete the
metabolite at a ratio equal to that measured in the metabolomics data. Thus, this approach does
not constrain the uptake or secretion flux of metabolites to a fixed value but instead constrains
the ratio of these fluxes between the two cell types (for more details on this approach, please read
method M9 in paper III).
Host cell proteins competing for most with EPO
After constraining the protein secretion models based on the proteomic and metabolomic data, I
aimed to identify which secretory proteins exhibit the highest competition with EPO over cell
resources. Knockout of such proteins (assuming that these proteins are not essential for
fundamental cellular tasks) is expected to affect EPO production positively. For this purpose, I
blocked the production of each secretory protein individually and maximized EPO production.
The resulting list of proteins was sorted based on their effect on EPO production. Figure 19C
shows the cumulative effect of the top 20 secretory proteins whose knockout may improve EPO
production.
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Figure 19. Genome-scale models assist with detecting host cell proteins that compete with EPO
production. (A) Pipeline for generating protein secretion GEMs constrained by metabolomics and
proteomics data (B) Categories of proteins detected in proteomics datasets. Proteins that were detected in
our proteomics datasets and either carry an ER signal peptide (554 proteins) or have an extracellular
predicted location (168 proteins) were included in the protein secretion model (559 protein in total, red
and purple areas). (C) The predicted cumulative effect of knocking out the top 20 host cell proteins
exhibiting the highest competition with EPO production for cellular resources.
This study identified the most significant alterations in different omics layers of a high EPO
producer cell line compared to its parental clone and a low producer cell line. I suggested a
hypothesis for connecting observed changes in the higher EPO producer clone after further
testing and validation could be deployed for cell factory development purposes. Furthermore, I
developed a constraint-based modeling approach and generated a metabolic model covering the
protein secretion process. First, I constrained the protein secretion model using multi-omics data
to improve model predictions. Next, I used protein secretion models for the higher EPO
producing cell-line to predict host cell proteins whose knockout could improve EPO production.
Finally, I provided the algorithm and resources for generating such models in a publicly available
toolbox called HumanSec that could be used for similar studies to develop more efficient cell
factories.
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Analysis of the protein secretory pathway in cancer (Paper IV)
Alterations in the expression of protein secretory pathway (PSP) components may cause many
abnormalities within the cell (Shiyu Wang and Kaufman 2012; Lebeaupin, Yong, and Kaufman
2020; Costa et al. 2020; Feizi, Banaei-Esfahani, and Nielsen 2015). It has been shown that the
collection of proteins secreted from the cell (the secretome) has a great potential to be used as a
reservoir for severe diseases biomarkers (Robinson et al. 2019; Welsh et al. 2003; Stastna and
Van Eyk 2012), or even as a reservoir of targets for developing new drugs against such
abnormalities (Ding et al. 2020; Khanabdali et al. 2016; Schaaij-Visser et al. 2013). However, all
proteins in the secretome are produced and processed by a core set of protein components, called
the protein secretory pathway (PSP). Feizi et al. previously demonstrated that PSP genes in
healthy tissues are expressed in a tissue-specific pattern to meet the production demands of the
secretome in each specific tissue (Feizi et al. 2017). Furthermore, previous studies included in
this thesis confirmed the presence of particular patterns of PTMs and responses to unfolded
proteins that exist in different cell lines (Saghaleyni et al. 2020).
Machine learning analysis of the cancer transcriptome
I retrieved the expression profile of 575 PSP genes (Feizi et al. 2017) from 11,053 RNA-seq
profiles deposited in The Cancer Genome Atlas (TCGA) (Table 1). These samples were
annotated with cancer type (33 different types) and the stage of cancer progression (from stage I
to stage IV, Figure 20A). Eight different machine learning classifiers were trained and evaluated
using a 10-fold cross-validation approach (Figure 20B) to (I) classify samples based on the
expression profile of PSP genes and (II) score the level of importance of each feature (gene) in
predicting sample classes (Figure 20C). I defined sample classes based on cancer status (normal
or tumor) and the status of cancer progression from stage I to stage IV. A gene scoring approach
was developed to predict the level of importance of each feature (gene) in predicting sample
classes (Figure 20C). The machine learning algorithms used in this study were random forests
(Ho 1995), highly randomized trees (ExTrees) (Geurts, Ernst, and Wehenkel 2006), adaptive
boosting (AdaBoost) (Freund and Schapire 1997), extreme gradient boosted trees (XGBoost)
(Freund and Schapire 1997), linear discriminant analysis (T. Chen and Guestrin 2016), lasso
regression (Tibshirani 1996), ridge regression, and support vector machine (Boser, Guyon, and
Vapnik 1992). These algorithms cover some of the most commonly used methods in machine
learning studies on biological data (Tarca et al. 2007; Sommer and Gerlich 2013) and also span a
good range of disciplines such as ensemble learning (random forests, ExTrees), regularized
logistic regression (lasso and ridge regression), and boosting (AdaBoost, XGBoost).
Furthermore, it is possible to calculate feature importance scores using all these algorithms.
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Figure 20. Schematic of machine learning analysis and feature scoring approach. (A) Expression data
for 575 protein secretory pathway (PSP) components extracted from RNA-seq expression profiles of
11,053 samples from 33 different cancer types. (B) Eight different machine learning (ML) classifiers were
trained using a 10-fold cross-validation approach to predict different binary classes, such as normal or
tumor, and also different stages of the cancers, for example, stage I or stage II, etc. (C) ROC AUC curves
used for evaluation of prediction performance for each model, as well as a feature importance score
ranging from 0-1 calculated for each gene and ML algorithm and also averaged across all ML algorithms.
Machine learning approaches detect PSP genes that are regulated by P53
Out of the 575 PSP genes present in our analysis, four are directly regulated by the p53 protein
encoded by the TP53 gene and one of the most commonly mutated oncogenes in different cancer
types (Ozaki and Nakagawara 2011). The four p53-regulated genes are BCL2 Associated X
(BAX), Heat Shock Protein Family A Member 4 Like (HSPA4L), Kinesin Family Member 23
(KIF23), and BCL2 Antagonist/Killer 1 (BAK1) (Graupner et al. 2011; Martin Fischer et al.
2013; M. Fischer 2017). Since a mutation in TP53 is likely to affect the expression of these
genes, by training ML models that classify TP53 mutated and TP53 non-mutated samples, I
expected to find these four genes among the top important genes that contribute to the
classification model. The average ROC AUC values across all ML algorithms classifying
different types of cancer was 0.74 ± 0.11 (Figure 21A). The averaged consensus ML gene score
across all cancer types identified three out of four genes that p53 directly regulates to have the
highest consensus score among the 575 PSP genes (BAX, HSPA4L, and KIF23, Figure 21B).
Figure 21. ML algorithms succeed in identifying genes that are regulated by p53. (A) Box plot of
ROC AUC values categorized based on the cancer types. (B) Histogram of consensus gene scores
calculated from ML analysis across all cancer types shows three out of the four PSP genes that are known









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































PSP genes associated with malignant transformation
The high scores of the three p53-regulated genes when classifying p53 mutated and p53
non-mutated samples confirmed that the ML approaches could capture relevant biological
features associated with a phenotype. I next sought to train models for classifying normal vs.
tumor samples and find the most relevant genes contributing to this classification (Figure 22A).
By comparing the results of finding the most important genes detected through machine learning
(ML) analysis with the results of differential expression (DE) analysis (Figure 22B), I found
similarities and differences between the two approaches. The ROC AUC values indicating
predicting the performance of normal vs. tumor based on the expression of PSP genes were
substantially higher (0.97 ± 0.03) than the analogous analysis for detecting p53 mutated vs. p53
non-mutated samples (Figure 2 of paper IV). The higher prediction performance of ML methods
in comparing cancer vs. normal compared to p53 binary mutation analysis is likely due to the
greater physiological differences between normal and cancer cells than between tumor cells
differing in a single gene mutation.
Figure 22. Glycosylation is enriched among top-scoring PSP genes from ML analysis for a subset of
cancer types. Top ten scoring genes from (A) ML analysis of normal vs. tumor samples and (B)
differential expression analysis of tumor against normal samples. (C) Glycosylation activity is enriched
among the top PSP genes from ML analysis (3 out of 5 top genes in 5 different cancer types: STAD,
COAD, READ, KICH, and THCA).
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Investigation of the top-scoring genes by the ML and DE approaches revealed kinesin-6 family
proteins (KIF20A and KIF23), Crystallin Alpha B (CRYAB), and several genes belonging to the
soluble N-ethylmaleimide-sensitive-factor attachment protein receptor (SNARE) family (STX1A,
STX12, STX11, and VAMP2) generally scored highly in both ML and DE approaches among the
different cancer types (Figure 22A-B). KIF20A and KIF23, two top-scoring genes in the ML
analysis (Figure 22A) that also exhibited significant (FDR adjusted p-value < 0.01) expression
increase in comparing tumor and normal (expression increase in 16 out of 18 cancers, Figure
22A), are already under investigation in clinical trial studies, as targets that whose inhibition may
help in stopping cancer progression (Rath and Kozielski 2012). KIF20A and KIF23 are involved
in Golgi-to-ER retrograde transport and have critical regulatory roles in mitosis and cytokinesis
(Baron and Barr 2015; Lai et al. 2000). These results indicated the ability of ML methods in
detecting genes that stood out in comparative DE analysis and suggested that other genes that
were only detected by ML approaches could potentially have critical roles in cancer progression.
For instance, from the STX proteins family, I detected STX12 in the results of DE analysis, but
STX1A and STX11 scored between top genes in ML analysis (Figure 22A). The STX family
supports various potentially tumorigenic functions such as autophagy and cell division (Jahn and
Scheller 2006). Hence, these proteins could serve as targets with potential for further anti-cancer
therapy studies (J. Meng and Wang 2015).
Besides several genes (STX1A, STX11, CRYAB) that were among top-scoring genes by averaging
over all cancer vs. normal comparisons, other top-scoring genes did not exhibit consistent high
scores in more than a few of the cancer types. For instance, almost all ML algorithms predicted a
high score (consensus score = 0.82) for RAS oncogene family member 17 (RAB17) in analyzing
prostate adenocarcinoma (PRAD) cancer samples. The RAB proteins family regulate vesicle
trafficking and promote and suppress tumor growth, depending on the family member and cancer
type (Gopal Krishnan et al. 2020).
Investigating the highest-scoring genes across all cancer types revealed a high frequency of genes
associated with glycosylation. In particular, in five cancer types, STAD, READ, COAD, KICH,
and THCA, 3 out of 5 top-scoring genes are known to participate in glycosylation activity
(Figure 22C). This highlights the potential role of a protein's glycan pattern in dictating cellular
functions such as cell adhesion, differentiation, and signal transduction that could promote cancer
progression (Cummings and Pierce 2014).
PSP genes associated with tumor stages
I grouped tumor samples into four stages: I, II, III, and IV. To avoid the oversimplification and to
assume an equal, linear change in disease severity of the different tumor stages, I took a binary
approach to perform pairwise comparisons of different stages (e.g., I vs. II, I vs. III, II vs. IV,
etc.) within each cancer type by training ML classifiers analogous to the same binary
classification scheme that I used in the previous sections of this study. I performed the analysis
on 20 cancer types, excluding cancer types without at least ten samples in at least two different
tumor stages.
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As expected, the class prediction performance (ROC AUC) for tumor stage predictions was
substantially lower than those trained to predict normal vs. tumor samples (Figure 23A). The
difference in the physiological status between different stages of cancer is relatively subtle
compared to differences between normal and tumor samples. However, the distribution of ROC
AUC values showed a cancer-specific pattern. Therefore, I only selected the trained models for
the ten cancer types with the highest ROC AUC values for further investigation.
Across all ten different cancer types, KIF20A, on average, indicated the highest score (Figure
23B), particularly for separating tumor stages of KIRP, and to a lesser extent, KIRC and ACC.
Although KIF20A in most cancer types showed either a higher ML score or a significant change
in DE analysis in renal carcinomas (KIRP, KICH, and KIRC), I did not observe such a pattern.
To investigate this behavior, I compared the expression of KIF20A across different tumor stages
and cancer types, along with normal samples (Figure 23C). In most cancer types, KIF20A
indicates a more step-like pattern of change between normal and cancerous cells, while in renal
carcinoma samples, KIF20A expression increases gradually with increasing tumor stage. KIF20A
has been highlighted in other studies as one of the risk factors involved in developing many
different cancer types (Rath and Kozielski 2012; W. Zhang et al. 2016; Gasnereau et al. 2012).
However, its involvement in renal carcinoma has not yet been addressed. The KIF20A expression
alterations observed in the current study suggest that this gene may support more invasive and
metastatic functions associated with later stages of renal carcinoma and thus constitutes a
potential therapeutic target for this cancer type.
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Figure 23. PSP genes associated with tumor stage. (A) Distribution of ROC AUC values for the
prediction of tumor stages in each cancer type using PSP gens. (B) Top-scoring genes across all ML
algorithms and cancer types. (C) KIF20A expression (log2 transformed TPM) among different cancer
types and grouped by tumor stage.
In this study, I implemented a dual ML–DE approach to analyze 575 PSP genes in 11,053 healthy
and cancerous RNA-seq profiles spanning 33 different cancer types. Besides investigating the
selective potential of PSP genes in cancer diagnosis, selecting this subset of genes had the benefit
of reducing the number of features for ML analysis. I validated the performance of our developed
ML pipeline by detecting known targets of P53 among the 575 PSP genes (BAX, HSPA4L, and
KIF23).
I then used the pipeline to find critical genes that had the highest contribution in classifying
normal and cancerous samples. Through this analysis, I identified patterns in PSP expression that
were common to carcinogenesis independent of cancer type. However, I also explored secretory
elements that indicated a cancer-type-specific behavior. Finally, by training models for
classifying samples from different tumor stages for each specific cancer type, I assessed the
potential of ML approaches to identify genes relevant to tumor progression and potential for
cancer treatment applications.
A recurring gene in our analysis was KIF20A. This gene was detected as top-scoring in nearly all
ML and DE analyses: P53 mutated vs. P53 non-mutated, tumor vs. cancer, and comparison of
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tumor stages. This observation is supported by the many different studies on the potential roles of
KIF20A in cancer progression and tumor aggressiveness (W. Zhang et al. 2016). In addition, I
detected a different pattern of expression for the KIF20A gene in samples from renal carcinomas
(KICH, KIRP, KIRC). KIF20A exhibited a sharp difference in expression between normal and
cancerous samples in most cancer types and remained relatively constant among different tumor
stages. However, in renal carcinoma samples, I observed a gradual increase in the expression of
this gene with increasing tumor stage. These observations support the further exploration of





The behavior of cells, as the smallest functional and structural unit of living systems
(Jensen-Jarolim 2014), depends on the status of their internal components and the surrounding
environment (Berg, Tymoczko, and Stryer 2002). Hence, predicting cell behavior requires
accurate modeling of its inner components and must consider the effect of environmental
conditions (B. Palsson 2006). However, there is an enormous number of reactions and
interactions taking place within a cell. Genome-scale metabolic models (GEMs) greatly help with
organizing the information on metabolic reactions within the cell in a unified manner (B. Palsson
2006), and flux balance analysis (FBA) approaches enables predictions of metabolites
concentration changes and reaction fluxes (Orth, Thiele, and Palsson 2010). However, GEM
reconstruction and FBA simulations involve many assumptions that are not always explicitly
stated (O’Brien, Monk, and Palsson 2015). Although these assumptions enable computational
simulations, they simplify the metabolic and physiological characteristics of the cell (Fang,
Lloyd, and Palsson 2020). For example, many pathways such as transcription, translation,
signaling pathways, protein secretion, and apoptosis are usually not included in classical GEMs.
Furthermore, classical GEMs do not consider some of the spatiotemporal and physicochemical
limitations; For instance, limitations in protein allocation for each reaction or limitations could
affect reaction fluxes due to resource or spatial constraints.
Omics approaches can greatly improve our knowledge about the different components within
cells from a global perspective. For instance, performing the transcriptomic analysis can provide
information about all RNA transcripts in a cell while also providing comparative information
about the relative levels of each transcript (B. Wang et al. 2019). The same applies to proteomics
and metabolomics analysis (Di Girolamo et al. 2013). This information can help address the
challenges of generating more advanced GEMs, with fewer simplifications and more accurate
biological predictions (Hyduke, Lewis, and Palsson 2013). However, in most cases, information
retrieved from omics analysis cannot be directly incorporated into GEMs (Yizhak et al. 2010).
Thus, contextualizing omics information using GEMs needs proper approaches that can either
use this data for increasing the coverage of a GEM’s reactions or for extracting information that
could be used as biological constraints (Yizhak et al. 2010; Dahal et al. 2020; Volkova et al.
2020; Ramon, Gollub, and Stelling 2018). The knowledge provided by omics datasets has been
used so far in different studies to improve GEM coverage and predictions (H. Wang et al. 2018;
Domenzain et al. 2021; Pandey, Hadadi, and Hatzimanikatis 2019). However, there is still a lack
of unified methodology for reconstructing GEMs using multiple different omics datasets. Ideally,
datasets such as transcriptomics, proteomics, and metabolomics could be used as input to
generate a GEM with high reaction coverage and biologically accurate flux constraints.
One major challenge in developing such an algorithm is that the data in some omics approaches
such as metabolomics and proteomics are reported as relative values between samples, which are
not compatible with most current standard methods for generating GEMs constraining reactions
performing FBA. Hence, to integrate data from comparative omics datasets into GEMs, we need
to develop improved approaches for estimating the absolute values from relative values (Sánchez
et al. 2021) or by improving algorithms that can reconstruct GEMs and incorporate FBA
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constraints in a comparative mode for two or more samples. In the current thesis, I deployed the
latter approach to predict the relative production of secretory proteins between two models (paper
III). The promising results of this analysis could be a positive sign for developing an approach
that could take into account the corresponding values for all proteins and metabolites and
constrain similar reactions in two models based on these data. However, applying this approach
on enzymatic proteins with complex promiscuous or isozyme relationships will further
complicate the approach. Although expanding this approach to cover enzymatic reactions
demands further formulation, it could be a way of reconstructing more enriched GEMs with more
precise flux distribution predictions.
In a part of the current thesis, I described a pipeline for generating human GEMs that cover
reactions in the protein secretory pathway. However, this pipeline is not able to predict the
pattern of PTMs on each protein. As PTMs have a critical role in protein functionality, a possible
way of expanding protein secretion models could be to expand them to cover and predict PTM
patterns. For this purpose, we need to keep in mind that environmental conditions such as culture
media and culturing processes and the status of signaling pathways within the cell could
substantially affect the variability of alterations in the patterns of PTMs, presenting a challenge in
modeling this process.
Tegel et al. indicated (Tegel et al. 2020) CHO and HEK293 cells have different power for
producing various human secretory proteins. Thus, another potential application of protein
secretion models might be using cell-factory-specific protein secretion models to find the most
efficient cell factories to produce each protein of interest. Furthermore, by reconstructing such
models and applying proper constraints based on culture media composition and culturing
conditions, we could capture and learn how each cell factory’s metabolism supports the
production of different proteins. Solutions provided by protein secretion GEMs could greatly
optimize the variables in the culturing process, such as culture media composition, and also be
used for finding targets for cell factory design.
A well-constraint protein secretion GEM could be a powerful tool for analyzing samples from
diseases that the protein secretion process plays a vital role in, e.g., Alzheimer’s diseases and
Parkinson’s diseases (L. C. Walker and LeVine 2012). Although there are different hypotheses
regarding the leading cause of deficiency in protein production and secretion in such disorders,
the main reason is unknown (Long and Holtzman 2019). However, various studies have shown
metabolism-related deficiencies, such as shortage in the power of energy production and
imbalance redox condition, could have a significant role in causing such diseases (Long and
Holtzman 2019; W. T. Wang et al. 2019; Ferreira et al. 2010). Protein secretion GEMs connect
metabolism to the protein secretion pathway. So, these models potentially could serve as
powerful tools for analyzing proteopathy disorders and finding biomarkers and drug targets in the
metabolism that lead to the progression of proteopathy disorders.
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Conclusion
Protein secretion is a multi-compartmental process catalyzed by many reactions within the cell
and changes under various situations such as the production of a recombinant protein or disease.
In the current thesis, I studied the protein secretion pathway in human cells using systems
biology tools.
In paper I, I compared multiple strains of HEK293 cells, a recombinant protein production cell
factory, to discover the key differences that could lead to better adaptation of cell lines from
adherent to suspension culturing. I identified genes with a high potential to regulate this process.
In paper II, I compared cell lines that were producing a recombinant secretory protein with those
that were producing a non-secretory protein. I observed that alterations in energy metabolism
appeared to support higher protein production. I showed that higher protein producer cells
dedicate more protein resources to overexpress mitochondrial genes that are involved in the
electron transport chain, and through this provide more energy resources for recombinant protein
production.
In paper III, I compared transcriptome, proteome, and metabolome between EPO-producer
clones that produced EPO at different rates and investigated genes, proteins, and metabolites that
potentially play more critical roles in the protein production process. These analyses suggested an
important effect of activating the mTORC1 signaling pathway to boost protein production and
reducing apoptosis. I expanded the human GEM to cover the protein secretion process in human
cells and predicted proteins whose synthesis competes for metabolic resources with our
recombinant protein of interest. To integrate relative metabolite abundance data for boundary
metabolite constraints, I developed an approach that constrains the models based on relative
protein abundances. I used a similar approach for constraining the production of secretory
proteins by the model. These efforts could be continued in future studies for defining an approach
that can implement relative values from proteomics and metabolomics analyses as soft
constraints on the model’s reactions and improve predictions.
In paper IV, I investigated the expression profiles of protein secretion pathway genes across
samples from 33 different cancer types. I used a machine learning approach to predict important
genes associated with differences between tumor and normal samples, as well as between
different tumors. Our analyses in this study highlight: (I) PSP genes could potentially serve as a
source for new anti-cancer drug targets, and (II) in analyzing RNA-seq data, applying different
analytical approaches can supplement and complement more common methods such as
differential gene expression, thus providing a more complete picture of the biological differences
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